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1.1. ERBB receptor family 
 
ERBB receptor family, originally named because of their homology to the erythroblastoma 
viral gene product, v-erb, forms the subclass I of the receptor tyrosine kinase (RTK) 
superfamily composed by four members namely ErbB1 (EGFR or HER1) ErbB2 (HER2/neu), 
ErbB3 (HER3) and ErbB4 (HER4)1 and 13 polypeptides extracellular ligands, with a 
conserved Epidermal Growth Factor (EGF)-like domain2. 
The ERBB family is expressed in several tissues but primarily include those of epithelial, 
mesenchymal and neuronal origin. Indeed, in normal cells the ERBB axes serves a crucial 
role in development, proliferation and organogenesis3.  
ERBB family members are structurally related and shares the same structural features. Each 
receptor is composed of three functional domains: an extracellular domain responsible for 
ligand-binding (domain I-IV), the a-helical transmembrane segment and the intracellular 
protein tyrosine kinase domain that also contains motifs and residues that mediate 
interactions with intracellular signalling molecules (Fig. 1A).  
Under homeostatic conditions, receptor activation is tightly regulated by the availability 
of ligands. The family of ligands that bind ERBB receptors, is divided into three distinct 
groups. The first includes epidermal growth factor (EGF), transforming growth factor alpha 
(TGFα) and amphiregulin (AR), which all bind specifically to EGFR. The second group 
includes betacellulin (BTC), heparin-binding EGF (HB-EGF) and epiregulin (EPR), which 
bind to both EGFR and HER4. The third group is composed of the neuregulins (NRG1-4) 
and subdivided on their ability to bind both HER3 and HER4 (NRG1 and NRG2) or only 
HER4 (NRG3 and NRG4)4. 
Upon ligands binding all members of ERBB family are able to form heterodimers with other 
members, while only ERBB1 and ERBB4 can form active homodimers (Fig. 1B).  
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Two members of the family, ERBB2 and ERBB3, are non-autonomous. ERBB2 lacks the 
capacity to interact with a growth factor ligand5, whereas the kinase activity of ERBB3 is 
defective 6. Nevertheless, both ERBB2 and ERBB3 form heterodimeric complexes with the 
other members of ERBB receptor family and activate strong cellular signals.  
Although ERBB2 does not bind to EGF-like ligands, it functions as the preferred 
heterodimeric partner of the other three ERBB members7. Furthermore, ERBB2-containing 
heterodimers are characterized by a higher affinity and broader specificity for various 
ligands than the other heterodimeric receptor complexes, owing to slow rates of growth-
factor dissociations. Also, ERBB2-containing heterodimers undergo slow endocytosis, and 
they more frequently recycle back to the cell surface8. These features translate to potent 
mitogenic signals owing to the simultaneous and prolonged recruitment of multiple 
signalling pathways.  
ERBB3, the kinase-defective receptor binds to four ligands, and forms three functional 
heterodimers. On the heterodimerization, the cytoplasmic domain of ERBB3 undergoes 
tyrosine phosphorylation and can recruit PI3K to six distinct sites and Shc to one site. 
Although there is no site for GRB2. This segregation enables ERBB3 to evade ligand-induced 
degradation9. 
ERBB4 shares recognition and signaling with ERBB1. They both bind to a large and distinct 
group of ligands i.e., betacellulin and the heparin-binding ligand, HB-EGF, as well as the 
two low-affinity ligands, epiregulin and epigen. Like ERBB1, ERBB4 recruits GRB2, Shc and 
STAT5. Although ERBB4 might not be able to directly recruit Cbl, and therefore 
downregulation of this receptor is slow, a proteolytic cleavage product of the cytoplasmic 
domain of ERBB4 translocate to the nucleus and might possess transcriptional activity10. 
Cellular response to ErbB pathways ranges from cell division and migration to adhesion, 
differentiation, and apoptosis. Output depends on cellular context, as well as specific ligand 
and ERBB dimers formation (Fig. 1B). For example, homodimeric receptor formation are 
less mitogenic and transforming than the corresponding heterodimeric combination; ErbB2 
containing heterodimers are the most potent complex, i.e. ErbB2-ErbB3 heterodimer induces 
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Figure 1: ErbB receptor family structure and signaling network. (A) Epidermal Growth factor receptor 
(EGFR), ERBB3 and ERBB4 exist in a tethered conformation in which the dimerization domain is not available 
to interact with partner ErbB moieties in the absence of ligand. There is no known ligand for ERBB2 and this 
receptor exists in an active extended conformation permanently available for dimerization. Adapted from J. 
Baselga, Nature review, 2000. (B) Ligands binding to ErbB receptor induces a conformational change in the 
folded structure exposing the dimerization domain. This step allows dimerization formation and functional 
activation of EGFR, ERBB3 and ERBB4. Through adaptor/enzymes molecules and transcription factors 
extracellular inputs are translated into several specific cellular responses such as apoptosis, migration, growth, 
adhesion and differentiation. Adapted from Y. Yarden, Nature Review 2001. 
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1.2. ERBB signalling network 
 
For decades ErbB pathway has been studied as a linear pathway: binding of the ligand to 
the monomeric receptor promotes receptor dimerization and self-phosphorylation on 
tyrosine residues in the catalytic domain. The issue of signalling specificity, along with the 
existence of non-autonomous RTKs and the broad range of EGF-induced biological 
outcomes, motivated a paradigm shift a decade ago; the view of simple pathways 
connecting ERBB protein to enzymatic processes and biological outcomes has given way to 
a web of interconnected pipelines, called the EGFR/ERBB network 1. In higher eukaryotes, 
this linear pathway has evolved into a richly interactive, multi-layered network conferring 
selective gains in terms of adaptation, tolerance to mutations and signal diversification 13.  
From a system-biology view, several functional features of the ERBB network contribute to 
the robustness of the signalling, sharing traits with complex biological and engineered 
systems14. The robustness of biological system is an inherent system property, which enables 
normal performance despite external and internal perturbation15. Several attributes are 
shared by robust systems of eukaryotic and prokaryotic organisms, as well as by 
engineering systems, and they might collectively function as the framework that underlies 
robustness14, namely network architecture, modularity, system controls, redundancy and 
buffering.  
The network architecture is characterized by a layered structure, that interfaces with the 
input of multiple growth factors, functioning through eight potential receptors, hetero- or 
homodimers, activates common signalling cascades collectively defined as core process.  
This core process results in the specific activation of transcription factors that lead to the 
selected cell fate, characterized of interconnected subnetwork that modify signals in a highly 
reproducible manner unlike, the diverse sources of input and different output, the core is 
conserved. The input layer displays remarkable redundancy. For example, betacellulin can 
bind to and activates both ERBB1 and ERBB4, whereas epiregulin binds to ERBB1, ERBB3 
and ERBB4. The multiplicity of ERBB ligands feeds into the combinatorial nature of the 
ERBB network, in which homo- or heterodimeric receptors can be formed, thus establishing 
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a high level of complexity. Each ligand-driven receptor dimer possesses distinct functional 
properties in terms of binding affinity, endocytic routing and effector activation. 
Modularity, with a hierarchical configuration is divided into quasi-autonomous sub-
system. This configuration enables a system to locally contain inflicted damage and promote 
heritable phenotypic variation (evolvability).  
The system control level of positive and negative feedbacks helps to maintain dynamic 
relationship between inputs and outputs, within defined limits. In this regards, positive-
feedback loops enhance the amplitude and prolong the active state of signalling pathways 
to convey robustness in the face of variable inputs. In the case of ERBB ligand binding to the 
primary receptor is tuned by the identity of the secondary receptor. ERBB2 can be 
considered as an important positive regulator as it functions as preferred secondary 
receptor and ERBB2-containing heterodimers evade negative regulation8. Also Ras-MAPK 
pathway ERBB-mediated activation strongly induce the transcription of ERBB ligands 
including TGFa and HB-EGF16. A vast cellular effort is also invested for mechanisms of 
signal attenuation including post-translational modifications, compartmentalization, 
catalytic inactivation and steric hindrance. One of the most effective, irreversible process 
that robustly attenuates signalling, by targeting surface receptors, is receptor internalization 
coupled to degradation in lysosomes. Also, dephosphorylation is another mechanism of 
signal attenuation. For example, density-enhanced phosphates-1 (DEP1) dephosphorylate 
EGFR as well as other RTKs and protein tyrosine phosphatase-1B (PTPB1) which 
dephosphorylates RTKs in endosomes17,18. Newly synthetized attenuator defines the 
window of active signalling as their expression reach a peak after one hour. For example 
suppressor of cytokine signalling-5 (SOCS5) leads to a marked reduction in the levels of the 
receptor by promoting EGFR degradation, possibly via proteasome19. Two other newly 
synthetized attenuators, with a lower activation kinetics, are adaptor protein sprout (SPRY) 
and leucine-rich repeats and immunoglobulin-like domains-I (LRIG1) acting through Cbl, 
while mitogen-inducible gene-6 (MIG6) functions directly on the receptor20–22. 
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Redundancy is a functional degeneracy of individual components or whole modules which 
are non-identical, offers different ways to generate an output in the face of severe 
perturbations, thereby increasing functional plasticity. The ERBB network displays 
redundancy at each layer of the network, at the input level as well as in the core of the 
network. For example, in the pathway that leads to activation of Raf1 by son of sevenless 
(SOS), ERBB1 can recruit SOS through either GRB2 or Shc, whereas GRB2 can associate with 
the receptor either directly or through Shc23,24.  
Buffering is a protective mechanism that enables damaged components to maintain (to some 
extent) proper functioning, i.e. HSP90 is the main chaperon that refold mutated or otherwise 
perturbed proteins enabling normal activity. By contrast to other ERBB receptors, ERBB2 is 
the most prominent kinase target of HSP90 that stabilize ERBB2 at the plasma membrane; 
notably HSP90 is able to restrain ERBB2 kinase activity limiting the capacity of ERBB2 to 




1.3. EGFR pathway 
 
The autonomous receptor ERBB1 binds to multiple ligands and forms homodimers, as well 
as three functional heterodimers.  
Ligand binding to the leucine-rich repeats in domain I and III (due to the bivalent nature of 
the ligand) of the EGFR extracellular domain, triggers a conformational change in the 
receptor that exposes the dimerization loop (domain II) to other receptors on the cell surface. 
Exposure of domain II allows for homo or heterodimerization with other HERs family 
members activating EGFR kinase function (Fig. 3A). 
Several tyrosine-based motifs recruit a number of signal transducers to the phosphorylated 
form of ERBB1, such as the adaptor proteins GRB2 and Shc, which are responsible for the 
Figure 2: a system prospective of ERBB network. The ERBB network is characterized by three distinct layers namely 
the input, the signal-processing and the output layer. The Input layer comprising 13 growth factors that directly bind 
to three receptor ERBB1, ERBB3 and ERBB4. The signal processing layer composed by ERBB receptors (EGFR, ERBB3 
and ERBB4) the core process and transcription factors. The output layer that gives rise to cellular responses 
(proliferation, migration, differentiation and apoptosis) through multiple transcription factors. Depending on the 
exact combination of transcription factors and the cellular context, the output of the network regulates cell behavior. 
Positive (ERBB2, HB-EGFR, neuregulins (NRG) and TGFa) and negative feedbacks (Cbl, MIG6, LRIG1 and SPRY) act 
for system control, while HSP90 functioning as chaperone enabling damaged component to maintain proper function 
(buffering), act as molecular switch that regulates heterodimer formation and catalytic function as well as protein 
stability. A. Citri and Y. Yarden. Nature review 2006. 
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recruitment of Ras and activation of the mitogen-activated protein kinase (MAPK) cascades. 
The three primary signalling pathways activated by EGFR include, the RAS/RAF/MEK/ERK 
(ERK pathway), PI3K/AKT and JNK axes culminating in cell fate decisions. (Fig. 3B)  
ERK pathway regulate entry into the cell cycle, thus cell proliferation accounted as a central 
element in many human tumours. After ligand binding and autophosphorylation, C-
terminal phospho-tyrosine residues on EGFR act as binding site for the SH2-domain-
containing protein GRB2. GRB2 recruits the guanine nucleotide exchange factor SOS via its 
SH3 domain, and promotes binding of GTP to Ras, a small G-protein responsible for 
activation of the MAPK cascade. Ras-GTP initiates this cascade by binding to and activating 
the RAF kinase (MAPKKK). Activated RAF in turn binds to and phosphorylates MEK 
(MAPKK), which then phosphorylates ERK1/2 (MAPK). Upon activation, ERK kinases can 
translocate to the nucleus and activate several other kinases including MNK1 and MNK2, 
MSK1 and MSK2, and RSK. MAPK can also phosphorylate several transcription factors 
including Elk-1, peroxisome-proliferator-activated receptor γ (PPARγ), signal transducer 
and activator of transcription 1 and 3 (STAT1 and STAT3), C-myc and AP-1. Activation of 
transcription factors leads to an increased transcription of genes involved in cellular 
proliferation, most notably cyclin D126.  
PI3K/AKT pathway regulate cell survival. Activated RTKs can recruit PI3K to the cell 
membrane. PI3K phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) yields 
the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 serves as a 
membrane-docking site for the serine/threonine protein kinase AKT, which binds to PIP3 
with high affinity through its pleckstrin homology (PH) domain. Once positioned on the 
plasma membrane, AKT is phosphorylated by two kinases, phosphoinositide dependent 
kinase 1 (PDK1) and the mammalian target of rapamycin complex 2 (mTORC2), leading to 
its full activation. Phosphorylated AKT regulates a variety of different substrates, 
influencing cell survival, proliferation and cellular metabolism16. 
 9  
Figure 3: EGFR conformational change on ligand binding and signal pathway. (A) Ligand is able to contact 
domain I and III within the same receptor promoting substantial conformational changes in the extracellular 
region of EGFR which unmask the dimerization arm in domain II. Before ligand binding domain II is not 
exposed and EGFR is in a “tethered” state in which both ligand binding and dimerization domain are auto-
inhibited. Ligand binding break the tethered conformation allowing domain II to interact with a second ligand 
bound receptor molecule. (B) Schematic representation of EGFR signal pathways. Six EGFR ligands namely 
EGF, AREG, HB-EGF, TGF-a, epiregulin (EPR) and betacellulin (BTC) bind the receptor and induce the 
formation of homo- (ERBB1-ERBB1) or ethero-(ERBB1-ERBB2, ERBB1-ERBB3 and ERBB1-ERBB4) dimers. 
Three main signal axes are activated (JNK, PI3K/AKT and MAPK pathway) leading to different cell fate: 




To dynamically control the amplitude, kinetics and frequency of output signals, the ERBB 
network evolved positive- and negative-feedback circuits contributing to maintain 
robustness.  
Positive feedback loops enhance the amplitude and prolong the active state of signalling 
pathways to convey robustness in the face of variable inputs27. In the case of EGFR, the 
output following binding of the ligand to the receptor, is the identity of the secondary 
receptor and in this context ERBB2 can be considered as an important positive regulator 
functioning as the preferred secondary receptor and ERBB2-containing heterodimers evade 
negative regulation28. 
Another important mechanism of positive feedback is based on autocrine and paracrine 
loops in which EGF-like ligands, as well as angiogenic factors, are produced following 
receptor activation. For example ERBB-mediated activation of Ras-MAPK pathway strongly 
induces the transcription of multiple ERBB ligand, including TGFa and HB-EGF29. Similarly. 
Transactivation of ERBB1 by G-protein-coupled receptors occurs through the stimulation of 
surface proteinases, generating mature active HB-EGF16. 
On the other hand, negative feedback regulation plays a major role in restricting the activity 
of the EGFR, thus ensuring the generation of stable and reproducible signal output as, an 
excessive EGFR signalling might pose a serious oncogenic threat. Negative feedbacks can 
exert their function immediately (early loops) relying on pre-existing molecules comprising 
both protein translocations and post-translational modification. In addition, negative 
feedbacks can be driven by the synthesis of RNA and proteins (late loops). 
One major early negative feedback loop is ligand-induced receptor endocytosis where 
ligand binding to ERBB1 receptors and their subsequent dimerization induces receptor 
internalization into endosomes. They reach a tubulovesicular sorting or early endosomes 
from where they can either recycle back to the plasma membrane, following the route of 
transferrin receptor, or progress toward the lysosome for degradation30. In the endosomes, 
auto-phosphorylation of EGFR enables it to recruit GRB2 and E3 ubiquitin ligase Cbl and 
undergo ubiquitylation followed by proteasome degradation. Although receptor 
endocytosis is a major negative feedback loop, the internalized receptors remain active 
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while en route for recycling or degradation31 (Fig. 4A). Because activation-dependent 
internalization and degradation of EGFR crucially determine signalling duration this 
process is strictly regulated primarily by intercepting the stability and activity of Cbl or by 
reversing two essentials covalent modifications, ubiquitylation and phosphorylation. In 
contrast late loops, relying on newly induced RNAs and proteins, can be divided into three 
temporal phases: primary response, with immediate and delayed early genes (IEGs and 
DEGs) and secondary response genes (SRGs) (Fig. 4B). The IEGs have an initial wave of 
transcription up to 45 minutes from stimulation comprising a limited set of genes which 
have primarily positive activities. The group of DEGs are transcribed within 45-120 minutes 
from stimulus comprising both positively and negatively acting components. The SRGs 
>120 minutes confer stable phenotypes in a cell context-specific manner. 
Figure 4: EGFR negative feedbacks. 
(A) detailed description of EGFR 
ligand-induced endocytosis and early 
regulatory negative feedback. Ligand-
EGFR complex internalization can be 
either recycled or degraded in 
lysosomes (or muti-vescicular body). 
(B) Pink line shows immediately 
downregulated microRNA (ID-miRs) 
which allows the onset of immediate 
early genes (IEGs). Green line shows 
the time-frame of activation IEGs with a 
peak of transcription after 45 minutes. 
Blue line shows the wave of activation 
of delayed early gene (DEGs) with a 
peak of activation after 45-120 minutes 
while secondary response genes (SRGs) 
are depicted in yellow activated after 
120 from stimulus.  
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1.4. Colorectal cancer 
 
Aberrant expression or activity of the EGFR has been identified as an important biological 
factor in many human epithelial cancers including head and neck squamous cell carcinoma 
(HNSCC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), breast, pancreatic 
and brain cancer. 
CRC represents the main oncologic disease of gastrointestinal tract with an incidence of 1.2 
million cases per year. Nowadays, CRC is the second most common cancer among women, 
with 614,000 annual cases (9.2% of all female cancers) and the third most frequent male 
cancer, accounting 746,000 annual cases (10% of all male cancers) 32,33. Despite mortality has 
declined progressively in the past decades 34, CRC is the second most frequent cause of 
cancer-related death, both in Europe and in the USA, with an overall 600,000 deceases 
worldwide 35. At the time of diagnosis, 20-25% of patients have already developed 
metastases, while another 20-25% will evolve a metastatic disease afterwards 36. 
The etiological factors and pathogenetic mechanisms underlying CRC development is 
complex and heterogeneous. Contributory agents and mechanisms in CRC include dietary 
and lifestyle factors along with inherited and somatic mutations. Indeed, among the most 
significant risk factors for CRC aside from elder age and male sex, factors such as family 
history of colorectal cancer, smoking, alcohol abuse, reduced physical activity and an 
enriched diet in unsaturated fats and red meat have been correlated to an increased risk of 
CRC occurrence 37. 
CRC is traditionally divided in two types: the majority of 70-80% of cases are sporadic while 
around 20-30% of CRC are familial due to either uncommon or rare, high-risk syndromes 
such as lynch syndrome (LS), familial adenomatous polyposis (FAP) and a small subset 
caused by inflammatory bowel disease (IBD)38. Sporadic CRC that account for the most 
cases, is mainly characterized by genetic instability. Now, the main consensus is that two 
main molecular features are responsible for CRC development: chromosomal instability 
(CIN) and microsatellite instability (MSI). CIN, the canonical pathway, which account 80% 
of sporadic CRC follows the Fearon and Vogelstein model which correlates specific genetic 
events with evolving tissue morphology. According to this model defined multi-step path 
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starting from adenomas formation and ending with transition to malignancy and tumour 
progression occur, along with specific genetic alterations in tumour suppressors genes or 
oncogenes 39. On the other hand MSI is characterized by a huge accumulation of mutations 
in microsatellite sequences, short sequences repeated in tandem throughout the genome 
and arise in a defective DNA mismatch repair (MMR) genes context40. 
CRC is a frequently lethal disease with heterogeneous outcomes, in terms of its clinical 
manifestations, molecular characteristics, sensitivity to treatments and prognosis. 
Nowadays, clinopathological characteristics of CRCs along with MSI status, RAS and BRAF 
mutations are used in the clinical setting as prognostic and therapeutic markers. However, 
patients groups defined by these molecular markers still differ remarkably in outcome and 
therapy response. Different approaches have been able to delineate certain CRC subtypes, 
based on combination of clinical and histopathological parameters, gene expression, 
epigenetic and single gene characterization.  
Several molecular classifications based on the gene expression profile of the tumour exist. 
However, there are some differences between them, especially in terms of the number of 
proposed subtypes. The main molecular classifications that have been proposed for CRC 
are: colon cancer subtype (CCS) system41, the colorectal assigner (CRCA) system42, Colon 
cancer molecular subtype (CCMS) system43, CRC intrinsic subtypes44. 
To resolve inconsistencies among the reported gene expression-based CRC classifications 
and facilitate clinical translation, it has been established a general framework that integrates 
and compare multiple strategies for disease stratification in gene expression-based sub-
typing of CRC. Guinney et al.45 showed marked interconnectivity between six independent 
classification systems coalescing into four Consensus Molecular Subtypes (CMS) with 
distinguishing features. These molecular subtypes differ in their genetic and epigenetic 
characteristics, expression of signal pathways, and clinical features (Table 1).  
CSM1 represent 14% of CRC tumours characterized by MSI and strong immune infiltrate. 
Hypermutation is due to defective DNA mismatch repair with MSI (microsatellite 
instability) and MLH1 silencing and accordingly CpG island methylator phenotype (CIMP)-
high with frequent BRAF mutations, while having a low number of somatic copy-number 
 14 
alterations (SCNAs). Also, gene expression profiling furthermore revealed evidence of 
strong immune activation (immune response, PD-1 activation, NK cells, Th1 cell and 
cytotoxic T cell infiltration signatures) in CSM1, consistent with pathological descriptions 
of prominent tumour-infiltrating CD8+ cytotoxic T lymphocytes. Patients with the CSM1 
subtypes had a very poor survival rate after relapse46. 
CSM2 (canonical, 37%) epithelial, with marked WNT and MYC signalling activation. CSM3: 
(metabolic 13%) epithelial and evident metabolic dysregulation. The CMS4 subtype 
(mesenchymal, 23 %) CRC showed increased expression of epithelial-mesenchymal 
transition (EMT genes and evidence of prominent transforming growth factor-β activation, 
with expression of genes implicated in complement-associated inflammation, matrix 
remodelling, stromal invasion and angiogenesis. Patients with the CMS4 subtype had a 
worse overall survival and worse relapse-free survival than patients of the other groups 45.  
  
Table 1: Taxonomy of Colorectal cancer 
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1.5. Colorectal cancer treatments 
 
In spite of large-scale screening efforts CRC patients present advanced, metastatic disease. 
Metastatic CRC (mCRC) is considered incurable, remaining a significant cause of morbidity 
and mortality worldwide with an overall survival (OS) of 18 to 21 months47. Systemic 
chemotherapy in this setting has traditionally been based on fluorouracil, with the more 
recent introduction of other cytotoxic agents, irinotecan, oxaliplatin, and capecitabine48. 
As knowledge about cancer biology and genetics expands, new treatment targets have been 
discovered and drugs developed to affect tumours in more rational fashion than impacting 
all cells actively in the cell cycle.  
What is emerged from molecular studies is that CRC is a tumour highly dependent on EGFR 
playing a critical role in CRC carcinogenesis. For this reason, over the last three decades 
EGFR targeting has been intensively pursued as treatment strategy for mCRC. In 2004 FDA 
approved cetuximab (CTX) for patients with EGFR-expressing mCRC refractory to 
irinotecan-based chemotherapy. CTX exhibited promising antitumor activity in clinical 
trials as either monotherapy on in combination with chemotherapy and/or radiation, 
particularly in the setting of mCRC49. CTX is a chimeric mouse/human IgG1 mAbs that 
binds to the extracellular domain III of EGFR. Several CTX mechanism of action have been 
described so far (Fig. 5). 
In 2006 FDA approved panitumumab a fully humanized IgG2 antibody that binds with high 
affinity to the extracellular domain of EGFR. Panitumumab is used in combination with 
chemotherapy regimens for use in mCRC expressing EGFR, for patients who had 
progressed on or after initial therapy with similar mode of action to CTX50. 
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The role of angiogenesis and lymphangiogenesis in tumour growth is well established. 
Over-expression of vascular endothelial growth factor (VEGF) gene and high level of 
circulating VEGF protein are both associated with worse prognosis in CRC51. For this reason, 
Figure 5: mechanisms of action of cetuximab. (A, B) CTX interaction with the extracellular domain of EGFR 
partially blocks the ligand-binding domain and sterically hinders the correct extended conformation of the 
dimerization arm on domain II. Thus, cetuximab prevents both ligand binding and the proper exposure of the 
EGFR dimerization domain, preventing dimerization with other HER family members. (C) Cetuximab 
promotes the internalization and degradation of EGFR, abrogating its downstream signalling cascades. (D) 
Cetuximab induces arrest in the G1 phase of the cell cycle by increasing levels of p27kip1. This in turn results 
in increase in the dimerization of p27Kip1Cdk2 complexes, which ultimately prevents exit from G1125. (E) 
Activation of other proapoptotic molecules has also been reported. Inhibition of angiogenesis, blockade of 
EGFR activation by cetuximab and by low-MW tyrosine kinase inhibitors results in a significant decrease in 
tumour-cell production of angiogenic growth factors such as basic fibroblast growth factor, vascular 
endothelial growth factor, and interleukin-8. The decrease in angiogenic growth factors, in turn, correlates 
with a significant decrease in micro vessel density and an increase in apoptotic endothelial cells in human 
tumour xenografts. (F) Potentiation of apoptosis, in some cases, G1 arrest is followed by apoptosis, this can be 
attributed to the induction of Bax and activation of caspase 8. (G) Antibody-dependent cellular cytotoxicity 
(ADCC) mediated by CTX. Recruitment of macrophages and natural-killer cells (NKs) have cytotoxic effect in 
tumour cells. The activation of these cells takes place following binding CD16aa (FcyRIIIa). 
 
 17 
several agents to inhibit VEGF and the cognate receptors (VEGFR-1 and VEGFR-2) have 
been developed. 
The first VEGF/VEGFR targeted drug was bevacizumab, a recombinant humanized IgG1 
antibody against all isoforms of VEGF-A (Fig 6B), approved in 2004 by FDA, for use in 
combination with chemotherapy in the first-line treatment of mCRC. The VEGF is an 
integral component of the angiogenic switch. When secreted by tumour cells, VEGF binds 
to the extracellular domain of its receptor, VEGFR, stimulating a signalling cascade that 
results in activation of the angiogenic responses. When used alone, the efficacy of 
bevacizumab is limited; however, in combination with chemotherapy, it was originally 
shown to improve response rates (RRs), progression free survival (PFS) and overall survival 
(OS) in patients with mCRC52. 
In 2012 FDA approved aflibercept, a recombinant decoy VEGFR1 and VEGFR2 fusion 
protein, linked via the Fc segment of IgG1, with anti-angiogenic and vascular permeability 
activity targeting multiple members of the VEGF family, including VEGF-A, VEGF-B and 
placental growth factor 2 (PlGF-2) (Fig. 6C). Binding these growth factors prevents their 
activity at the VEGFR-1 and VEGFR-2 receptors, which are found on the surface of 
endothelial cells and leukocytes. Its activity results in regression of tumour vasculature, 
inhibition of new vascular growth and remodelling of surviving vasculature. 
The first mAb against VEGFR was approved by FDA in 2015 namely ramucirumab, a 
recombinant, fully humanized IgG1 monoclonal antibody directed against the extracellular 
domain of the VEFGR2 (Fig. 6D). It binds to this receptor with high affinity, and thereby 
blocks ligand binding, primarily VEGF-A but others as well. It was approved in April 2015 
for use in combination with FOLFIRI for the treatment of patients with mCRC who have 




Figure 6: monoclonal antibodies treatment for mCRC.  Epidermal growth factor receptor (EGFR) and 
vascular endothelial growth factor receptor (VEGFR) represent the main two targets intercepted in mCRC 
impairing proliferation, survival and angiogenesis. (A) Cetuximab (a chimeric mouse/human IgG1 antibody) 
and panitumumab (a fully humanized IgG2 antibody) were approved by FDA in 2005 and 2006 respectively 
for the treatment of mCRC. They both bind epidermal growth factor receptor (EGFR) blocking its function 
with different mechanism of action (see Fig. 5 for details). (B) Bevacizumab (a recombinant humanized IgG1 
antibody) is able to intercept all isoforms of VEGF-A. (C) Aflibercept is a recombinant decoy (approved by 
FDA in 2012) comprising the extracellular domain of VEGFR1 and VEGFR2 and Fc (IgG1) segment able to 
sequester VEGFA/B and PIGF-2 from the microenvironment preventing the binding of the ligands to the 
cognate receptor. (D) Ramucirumab is the first mAb against VEGFR2 approved by FDA in 2015. 
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1.6. CTX resistance 
 
In 1983 Sato et al. isolated four mouse hybridomas secreting immunoglobulin G (IgG) 
against EGFR on A431 cells. Three of the antibodies M225 IgG, M528 IgG and M579 IgG 
blocked 95% of EGF binding to human A431 cells as well as competing with each other in 
binding assay. Further, each antibody could immunoprecipitated EGFR from A431 cells, but 
not from three rodent cell lines tested, demonstrating their specificity. Finally, each antibody 
effectively blocked EGF-induced phosphorylation of the receptor resulting in reduced 
proliferative potential of the cell lines examined53. 
M225 resulted with higher anti-EGFR efficacy compared to M528 and M579. The clinical 
trial for M225 was successful but all patients developed human-anti-mouse antibodies. For 
this reason M225 was converted to a human:murine chimera C225 with an IgG1 Fc isotype. 
The Fc isotype was chosen for its potential to enhance the immune contribution to C225 
antitumor effects. Subsequently C225 IgG1 was developed for clinical use namely 
cetuximab (Figure 7). 
 
From early studies conducted in heavily pretreated chemotherapy-refractory patients and 
also in chemotherapy-naïve patients with mCRC, became clear that only 10% to 20% of 
Figure 7: Schematic representation of Cetuximab development and subunits. On the left murine 225 (M225) 
hybridoma comprising the Fc subunit and the EGFR binding domain (F(Ab’)2). Clinical trial on M225 mAb 
proved the development of human-anti-bouse antibodies. For this reason M225 was engineered to a 
human:murine chimera C225 (cetuximab) with an IgG1 Fc isotype (on the right in red) enhancing the 
antitumor efficacy by stimulating the host immune response against tumor. Cetuximab is currently utilized in 
the clinic as monotherapy or in combination with chemotherapy for the treatment of mCRC patients. 
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patients clinically benefited from anti-EGFR mAbs. These evidences triggered a flourish of 
studies on the molecular mechanisms of resistance to cetuximab. Resistance to CTX was 
associated to alteration of the target itself, bypass mechanisms, upregulation and activation 
of downstream effectors, or cross-talk between associated pathways which activate 
complementary cell survival and growth pathways54. Firstly, what emerged is that the 
expression level of EGFR was not correlated with clinical response to cetuximab and 
panitumumab55. These finding lead to subsequent investigations to the mutational status of 
EGFR immediate intracellular molecules, as molecular event associated with resistance to 
CTX56 namely KRAS, NRAS BRAF and PIKCA. Since then, a rapidly accumulating body of 
knowledge has indicated that resistance to EGFR blockade in mCRC is related to 
constitutive activation of signaling pathways downstream EGFR. Initial retrospective 
analyses led to the breakthrough finding that, patients with CRC carrying activating KRAS 
mutation do not benefit from cetuximab therapy57. KRAS mutation have since emerged as 
the major negative predictor of efficacy in patients receiving CTX, unequivocally confirmed 
by three large, randomized, phase III cetuximab clinical trials, OPUS, CRYSTAL and NCIC-
CTG, monotherapy study conducted in relapsed/refractory patients or those with 
contraindications to chemotherapy58. Given these results, European health authorities and 
FDA has restricted the use of CTX to patients with wild-type KRAS mCRC only. Mutation 
in KRAS led to continuous activation of the downstream ERK signaling, regardless of 
whether the EGFR is pharmacologically inactivated.  
Although the presence of RAS mutations accounts around 50% to 60% of patients with 
mCRC refractory to EGFR blockade, molecular alteration in additional nodes of the EGFR 
signaling network also seem to be clinically relevant. For example, mutations in BRAF have 
been recently shown to impair responsiveness to cetuximab in patients with mCRC. In a 
cohort of 132 patients none of the patients responsive to CTX displayed BRAF mutation 
while 11 of 79 non-responder carried BRAF V600E allele59. Of note KRAS and BRAF are 
known to be mutually exclusive in CRC. 
In addition to KRAS and BRAF, EGFR activate PI3K signaling pathway. From the overall 
analysis of the published works, it seems that PIK3CA mutations along with the loss of 
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PTEN are in fact associated with the resistance60. Importantly, although KRAS and BRAF 
seem to be mutually exclusive, PI3KCA mutation and loss of PTEN can coexist with 
KRAS/BRAF mutations. Furthermore, it has shown that PI3KCA mutations located in the 
exon 9 and 20 hotspots exert different biochemical and oncogenic properties and are 
differently activated by KRAS. Thus, considering the relative low frequencies, that can co-
occur with KRAS and BRAF, and the different oncogenic properties of the different PI3KCA 
mutations it will be necessary to analyze large cohorts of patients for definitive conclusion. 
It is likely that PI3KCA and PTEN status will be useful to further optimize the criteria for 
eligible patients however these two marker are not yet ready to be used in the clinic61. 
Recently data indicate that when expression of PTEN and mutations of KRAS, BRAF and 
PI3KCA are concomitantly assessed up to 70% of mCRC unlikely to respond to anti-EGFR 
therapies can be identified62 namely all-RAS wild-type. 
Clinical data indicate that even the best response obtained in KRAS/BRAF wild-type tumors 
are transient, and even in the best cases, they do not last for longer that 12 to 18 months63. 
Little is known why the response is temporary and, tumors after a massive initial reduction 
rapidly begin to regrow and concomitantly became refractory to further anti-EGFR 
treatment.  
Genetic alterations in the tyrosine kinase receptors other than EGFR can be accounted as 
mechanism of resistance, providing an alternate pathway of survival and/or proliferation. 
Genetic aberration of the tyrosine kinases ERBB2 and MET have been shown to bypass 
EGFR signaling and activate the MEK-ERK cascade. ERBB2 gene amplification was found 
in a small fraction of RAS and BRAF wild-type mCRC patient-derived xenograft 
unresponsive to CTX also, activation of ERBB2 signaling, dependent of either gene 
amplification or overproduction of the ERBB3 ligand heregulin was present in a subset of 
patients with mCRC exhibiting de novo resistance to CTX28,64. Another tyrosine kinase 
receptor, MET is amplified in a small fraction of RAS and BRAF wild-type mCRC patient-
derived xenografts unresponsive to CTX65. Therefore, these pathways may offer primary 
escape mechanisms allowing tumors to circumvent one pathway that has been 
pharmacologically blocked. 
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Non-genetic mechanisms could also play a role in resistance to EGFR blockade. Notably, in 
biopsies from patients who relapsed upon CTX therapy only a fraction of cells carry RAS 
mutations, suggesting that wild-type cells can also survive the treatments66. This finding 
suggests that non-genetic mechanisms could also play a role in driving acquired resistance 
to EGFR blockade. For example, recent data reported that wild-type cells can survive in the 
presence of CTX when in company with their resistance derivatives. Notably, it was found 
that cells bearing acquired RAS mutations over-secrete the EGFR ligands TGFa and 
amphiregulin which protect the surrounding wild type-cells67. 
Autocrine/paracrine loops and dependency on alternative pathways, that confer survival 
and/or proliferation advantages is an emerging field that could potentially explain the 
subsets of patients with de novo unknown resistance. For example, a study conducted with 
a cohort of 150 colorectal cancer xenopatients, associated poor response to CTX with 
increased abundance of a set of inflammatory cytokines, including IL-1a, IL-1b and IL-8 68. 
Moreover, has been reported that IL-1 receptor 1 (IL-1R1) expression predicts disease 
relapse free survival in a cohort of 1700 colorectal cancer patients, and it appears 
intriguingly associated to the CMS1, thus suggesting the employment of immunotherapy to 
this subtype of patients 69. 
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1.7. IL-1 in solid tumours 
 
During the last two decades inflammation has been accounted as a crucial feature of the 
malignant phenotype associated with 25% of all human cancers70. A causal relation between 
inflammation and cancer has been proposed by Virchow in 1863, who hypothesized that 
malignant neoplasms arise within a region of chronic inflammation causing tissue injuries 
and increased cell growth71. 
Interleukin-1 (IL-1), in this context has been proved to play a pivotal role in cancer 
development, showing to be up-regulated in several type of tumours of epithelial origin, 
including breast, colon, head and neck, lung, pancreas and melanomas72.  
In addition, patients with high levels of IL-1 have generally bad prognosis 73,74. IL-1 can be 
directly produced by cancer cells or it can “educate” cells, within the tumour 
microenvironment, to do so 75.  
For example, Hong et al. shown that intercepting IL-1a employing a MABp1a true human 
mAb, a cohort of 54 patients refractory to treatment displayed a disease control in 18 
different tumour types and, its efficacy was further confirmed in 2017, in a randomized, 
double-blinded, placebo-controlled, phase 3 clinical trial in a cohort of 333 advanced 
colorectal cancer patients76. In support to these findings, employing Canakinumab (an anti-
IL-1b mAb) significantly reduce the incident of lung cancer in a cohort of 10.061 patients77. 
More recently, Kaplanov et al. (2019) proved that a combined neutralization of IL-1b and 
PD-1 was responsible for an astonishing abrogation of tumour development in mammary 
carcinoma murine model78 and tumour-derived IL-1b is critical for shaping tumor 
microenvironment (TME) of pancreatic ductal adenocarcinoma (PDA) promoting 
immunosuppression cell populations in pancreatic cancer79. As a consequence, a number of 






Table 2: ongoing (August 2020) clinical trial testing anti-IL-1 drugs, alone or in combination with 
chemotherapy, in cancer therapy. Gelfo et al.  Int. J. Mol. Sci., 2020. 
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1.8. IL-1 receptor family 
 
IL-1 receptors (IL-1Rs) belong to the Ig-like receptor superfamily characterized by the 
presence of Toll/interleukin-1 receptor (TIR) domain, which is essential for IL-1 activities. 
In 1996, the link between TIR domain and innate immunity was identified for the first time. 
These receptors are now called Toll-like receptors (TLRs) and known to be involved in the 
innate immune response80. During the last ten years, IL-1R family has been expanded to 
coreceptors, decoy receptors, binding proteins, and inhibitor receptors. Particularly, IL-1 
family ligands include seven molecules with pro-inflammatory activity: IL-1a, IL-1b, IL-18, 
IL-33, IL-36a, b and g. These seven agonists bind 4 different receptors belonging to the IL-
1R family; IL-1a, and IL-1b bind IL-1RI (IL-1R1), IL-18 binds IL-18Ra (IL-1R5), IL-33 binds 
ST2 (IL-1R4) and IL-36a, b and g bind IL-1Rp2 (IL-1R6). Apart from IL-18 that uses an 
accessory protein, all the other IL-1 family ligands, through their binding, induce the 
cognate receptor to form a heterodimer with IL-1R accessory protein (IL-1RAcP, IL-1R3). 
The receptors are characterized by an extracellular domain consisting of three 
immunoglobulin (Ig)-like domains, a trans-membrane and an intracellular domain 
characterized by a TIR domain, shared by all TLR, essential for signalling via the MyD88 
adaptor protein. Once the complex is made (i.e., IL-1R1/IL-1RAcP/IL-1), the recruitment of 
the signalling adaptor, myeloid differentiation primary response 88 (MyD88), to the TIR 
domain initiates the signal cascade by phosphorylation of several kinases. This activation 
leads to the expression of a large number of inflammatory genes81,82 (Fig. 8) and, IL-1 remains 




As regulator of immunological and inflammatory responses, IL-1 exerts a crucial role in 
mediating autoinflammatory, autoimmune, infectious and degenerative diseases. In the 
central nervous system, IL-1 induces fever and the activation of hypothalamus-pituitary-
Figure 8: Schematic representation of IL-1 receptors family. Seven pro-inflammatory ligands (IL-1a and b, 
IL-18, IL-33, IL-36a, b and g) bind to four different heterodimeric receptors (IL-1R, IL-18R, IL-33R and IL-36R). 
IL1RAcP represent the co-receptor to which IL-1R1, ST2 and IL-1Rrp2 form heterodimers. IL-18Ra utilize IL-
18Rb for heterodimerization. After a ternary complex is formed namely receptor, co-receptor and ligand, TIR 
domain of each receptor chain approximate and can recruit MyD88, followed by phosphorylation of receptor-
associated kinases (IRAKs) and inhibitor of NF-kB kinase b (IKKb) resulting in a signal to the nucleus that lead 
to transcription of inflammatory genes. 
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adrenal (HPA) axis. Like the other ligands, IL-1a and IL-1b are encoded by distinct genes. 
Although they bind the same receptor and show similar biological properties, the impact 
on inflammation and cancer differs83. IL-1a (like IL-33) is active both in its precursor and 
cleaved forms and it is usually found as a cell-associated cytokine or secreted in the 
extracellular milieu, exerting a dual-function. The intracellular precursor (pro-IL1a) is 
constitutively expressed in epithelial layers of the gastrointestinal tract, lung, liver, kidney, 
endothelial cells, monocyte and astrocytes. It contains a nuclear localization sequence 
(NLS), responsible for a nuclear localization, where it modulates gene transcription 80–82,84. 
Upon apoptosis, cytosolic pro-IL-1a translocate into the nucleus and remains tightly bound 
to the chromatin, failing to induce inflammation. In contrast, in presence of necrotic signals, 
cytosolic pro-IL-1a, is released and fully active; it functions as alarmin by rapidly initiating 
a cascade of cytokines and chemokines which account for sterile inflammation85. 
Furthermore, the pro-IL-1a might behave as an oncoprotein since its expression induces 
neoplastic changes in cells. For example, it has been demonstrated that upon IL-1R1 
signalling blockade, pro-IL-1a stimulates IL-8 production in different cells and promotes 
inflammation86.  
Unlike IL-1a, the IL-1b precursor (pro-IL-1b) is not functionally active. It needs to be 
cleaved by intracellular caspase-1 or extracellular neutrophilic proteases in order to be 
active in the extracellular space82. Moreover, IL-1b is not expressed in homeostatic 
conditions, but it is induced upon inflammation and its secretion is tightly controlled at 
transcription, translation and post translational levels83. IL-1b is mainly produced in 
response to TLR stimuli by hematopoietic cells such as blood monocytes, tissue 




1.9. IL-1 Pathways 
 
The initial step in IL-1 signal transduction is a conformational change induced by ligand 
binding in the first extracellular domain of the IL-1RI that facilitates recruitment of IL-
1RacP. Through conserved cytosolic regions TIR domains, the trimeric complex quickly 
assembles two intracellular signalling proteins, MyD88 and IRAK (interleukin-1 receptor–
activated protein kinase) 4. IL-1, IL-1RI, IL-RAcP, MyD88, and IRAK4 form a stable IL-1–
induced first signalling module.  
This is paralleled by the (auto)phosphorylation of IRAK4, which subsequently 
phosphorylates IRAK1 and IRAK2, followed by the recruitment and oligomerization of 
tumour necrosis factor–associated factor (TRAF) 6. Both IRAK1 and 2 function as adaptors 
and protein kinases to transmit downstream signals.  
IRAK1/2 and TRAF6 dissociate from the initial receptor complex and TRAF6 serves as 
ubiquitin E3 ligase that together with UBC12-UEC1A (ubiquitin E2 ligase complex) form 
the second module, able to attach different polyubiquitin chains to several IL-1-signalling 
intermediates including IRAK1, TAB2/3 (transforming growth factor -b (TGF-b)-activated 
protein kinase binding protein 2 and 3) and TAK1 (TGF-b-activated protein kinase). This 
second module can be considered a node of signal diversification. Oligomerization of TAF6 
and subsequent formation of two TAK1 and MEKK3 signalling complexes activate three 
main pathways namely, NF-kB, JNK and p38 MAPK axes. IKK1, IKK2 and NEMO for the 
IKK complex. Activated IKK complex phosphorylates IkBa which promotes 
polyubiquitination and its proteasomal degradation, p50/p65 are released and translocate 
to the nucleus. p50/p65 bind the DNA in conserved sequences activating IL-1-responsive 
genes like IkBa, IL-6, IL-8, MCP1 and COX-287–89. Activation of TAK1 and MEKK3 also 
trigger activation of MKK3, 4. 6 and 7 activate JNK axis. JNK and c-Jun play a key role in 
IL-1 induced expression genes encoding for IL-6 and IL-8. On the other hand MKK3, 4 and 
6 activate p38 MAPK axes that play an important role to stabilize the mRNA and translation 
of newly made transcripts by inhibiting mRNA-destabilizing factors controlling the 
abundance of many IL-1-regulated transcripts90. 
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IL-1 signalling pathway is transient and different mechanisms and proteins are involved in 
the attenuation of the signal. The IL-1R binds the adaptor toll-interacting protein (TOLLIP), 
which inhibits IRAK1, targets internalized IL-1RI to endosomes, and is required for efficient 
degradation of IL-1R. IL-1 also activates several negative-feedback inhibitors that shut-off 
IL-1R signalling. p38 MAPK-mediated phosphorylation of TAB1 inactivates TAK1; p65 NF-
κB-mediated mRNA and protein synthesis of IκBα shuts-off the NF-κB response; and 
inducible expression of the gene encoding MAPK phosphatase 1 (MKP1) dephosphorylates 
active MAPKs91 (Fig. 9).  
Figure 9: schematic representation of IL-1 signaling pathway. IL-1 pathway is activated up ligand (IL-1) 
binding assembling the first module protein complex (composed by IL-1R1, IL-1RAcP and IL-1) this, in turn 
lead to the activation of the second module of proteins complex comprising E2 and E3 ligase able to activate a 
kinase cascade followed by a diversification of IL-1 signal. Three main axes are activated: NF-kB, JNK and p38 
MAPK. Through these three axes genes associated with inflammation response are transcribed. Blue and red 
depict negative and positive feedbacks respectively. In orange are depicted the three main pathways IL-1-
activated and in green proteins belonging to the three modules. 
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2. Aim of the thesis 
 
Epidermal Growth Factor Receptor (EGFR) activates a robust signaling network to which 
tumors often become addicted 92. Over the last three decades, EGFR targeting has been 
intensely pursued as a treatment strategy for metastatic colorectal cancer (mCRC). One 
approach uses monoclonal antibodies (mAbs) to inhibit the extracellular domain of EGFR, 
thus blocking natural ligands binding. Unfortunately, patients often develop resistance, 
with consequent tumor growth and relapse. Tumors heterogeneity has been addressed as 
the main culprit for multiple escaping mechanisms, reflecting the high level of molecular 
heterogeneity in each metastatic site. Mechanisms of cancer cell resistance include either 
acquisition of new mutations or non-genomic activation of alternative signaling routes and, 
in this context, a role of IL-1 is emerging. For example IL-1 expression proved to be elevated 
in human breast, colon, lung and head and neck cancers 93, and patients with IL-1 producing 
tumors have generally bad prognosis 72. Our studies, performed with a cohort of 150 
colorectal cancer xenopatients, associate poor response to CTX with increased abundance 
of a set of inflammatory cytokines, including IL-1a, IL-1b and IL-8 68.  
Stemming from these observations, our working hypothesis assumes that resistance to CTX 
is acquired, in a subset of CRC patients, through cell plasticity and consequent rewiring of 
signalling networks, which confer dependency on the IL1 pathway. This hypothesis 
foresees an auto-stimulatory feedback loop dependent on the IL-1 produced by the tumors, 
with consequent immunosuppression and tumor progression. Thus, combining IL-1 and 




3. Material and Methods 
3.1. Cells and reagents 
 
MCF10A cells were cultured with DMEM/F12 medium (GE Healthcare) as previously 
described 97 supplemented with 10 µg/ml Insulin (I6634, Sigma), 0.5 µg/ml Cholera Toxin 
(C8052, Sigma), 0.5 µg/ml hydrocortisone (H0888, Sigma), 5% heat inactivated horse serum 
and 10ng/ml EGF (E9644, SIGMA) and maintained in a 37 °C atmosphere containing 5% 
CO2 incubator. MCF10A were kindly provided by Yosef Yarden Laboratories.  
Caco-2 (human coloncancer adenocarcinoma) and MC38 (murine colorectal 
adenocarcinoma) cell lines were cultured with Dulbecco’s minimal essential medium 
(DMEM), supplemented with 10% of fetal bovine serum (FBS) and antibiotics (1% penicillin-
streptomycin) in a 37 °C atmosphere containing 5% CO2. Cells were routinely tested for 
mycoplasma contamination. 
3.2. Western blot 
 
Naïve and mEGFR MC38 cells were lysed with Novagen PhosphoSafe Extraction Reagent 
(EMD Millipore) plus Protease Inhibitors Cocktail (Sigma-Aldrich) and incubated for 10 
minutes on ice. Protein concentration in the supernatants was determined by DC Protein 
Assay (Bio-Rad) using bovine serum albumin as the standard. Proteins (30 µg of total lysate) 
were separated on 8% or 10% polyacrylamide gel and then transferred to polyvinylidene 
difluoride membranes (Bio-Rad). After blocking with PBS containing 0.1% tween 20 plus 
5% BSA (Bio-Rad) for one hour at room temperature, membranes were incubated overnight 
at 4°C with primary antibodies diluted in blocking buffer. The following primary antibodies 
were used: anti-AKT rabbit polyclonal antibody (100 ng/mL, #9272), anti-phospho-AKT 
(Ser473) (D9E) XP rabbit monoclonal antibody (100 ng/mL, #4060), anti-EGFR (D38B1) (29 
ng/mL, #4267), anti-EGFR phospho tyr1068 (D7A5) (423 ng/mL, #3777) (Cell Signaling 
Technology, Danvers, MA, USA); anti-ERK2 (D-2) mouse monoclonal antibody (200 ng/mL, 
sc-1647) and anti-p44/42 MAPK (Erk1/2) mouse monoclonal antibody (10 ng/mL, M1859, 
Sigma Aldrich, St. Louis, MO, USA). Anti-GAPDH was used as loading control. Peroxidase-
conjugated AffiniPure Goat Anti-Human IgG, Fc Fragment Specific (800 ng/mL, 109-035-
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098, Jackson ImmunoResearch, Ely, Cambridgeshire, UK). Protein was detected by 
incubation with anti-rabbit or -mouse horseradish peroxidase-labeled secondary antibody 
(Dako EnVision+ System- HRP Labelled Polymer) followed by chemiluminescent reaction 
(Clarity Western ECL Substrate, Bio-Rad). Chemiluminescence was detected with the 




Cells were seeded in 96-well plates, 2.000 cells for each well, in 100  l of 5% FBS medium. 
Quantification of initial time (time 0) was performed the following day using Alamar Blue 
(20  M) in medium 0% FBS, measuring the fluorescence after 5 hours of incubation. 
Fluorescence was quantified using VICTOR2TM 1420 multilabel counter (Perkin Elmer, 
Massachusetts, USA), at a wavelength of 595 nm. Cells were then treated according to the 
experiment and, after 72-96h proliferation was measured using Alamar Blue, following the 
same procedure. Data were analysed subtracting background values, normalizing the 
endpoint values on the initial time ones, calculating for each treatment the median value 
and transforming it as percentage of the untreated control. Data points represent the median 
+/- SD. 
 
3.4. Colony forming assay 
 
2.000 cells were seeded in 12-well plates in 1 ml of medium. Treatments were added 
immediately or the following day, according to the information included in the figure 
legends. After one weeks following treatments a picture of each well was taken and the 
covered area was measured using IncuCyte S3® Live-Cell Analysis system (Essen 
Bioscience). The mean value from covered area values returned by the software was 
calculated for each treatment and recorded as a percentage of control. 
 
3.5. Soft-agar  
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To inhibit cellular adhesion to the plastic surface, 6-well plates were covered with a layer of 
agar 0.6% (bottom agar). Agar 1.8% was autoclaved and diluted to 0.6% with full medium; 
2 ml of 0.6% agar was used to cover each well and the agar layer was left to dry before 
seeding cells. 5.000 cells for each well and treatments were added (in 2 ml of medium). After 
21 days of treatment, pictures of randomly non-overlapping spheroids for each well were 
collected using the microscope at 4X magnification. Spheroids of each picture were counted, 
and the length of the major and minor axis of each spheroid was measured using ImageJ 
Software. Axis values below 60 A.I. were excluded as not corresponding to mature 
spheroids and volume was calculated applying the sphere adapted formula (major axis x 
minor axis)2/2. 
 
3.6. Scratch assay 
 
40.000 MC38 or MC38 hEGFR cell per well were seeded in a 96-well ImageLock (Essen 
Bioscience Cat. No. #4379) and left settled over night in the incubator with standard 
condition (37°C, 5% CO2). The day after a wound has been created with a 96-pin IncuCyte 
WoundMaker Tool (Essen BioScience Cat. No. #4563) to simultaneously create a wound in 
all wells. Then the media was aspirated and well was washed twice with PBS, then 100 uL 
of FM 10% FBS supplemented with appropriate treatments was added as specified in the 
figure legend. Cell invasion was followed in time-laps for 12 hours. Statistical analysis and 
images were obtained using IncuCyte S3® Live-Cell Analysis system (Essen Bioscience) 
3.7. Invadopodia detection  and Gelatin degradation assay 
 
Dehydrated gelatin was reconstitute 1 mg/mL by adding 5mL of ddH2O to the vial. The 
stock (100uL) was stored at -20°C protected from light. The working solution was prepared 
heating the stock aliquot to 60°C (in a water bath) and dilute to the final concentration of 0.2 
mg/mL in PBS with 2% sucrose (keep the working solution protected from light). For the 
preparation of gelatine-coated coverslips gelatine working solution was heated to 60°C (in 
a water bath), then added 100uL over the first coverslip. Once the gelatine was evenly 
distributed and the excess removed the coverslip was placed in a 12-well plate protected 
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from light. Allow the coverslip to dry. 1mL of 0.5% glutaraldehyde was added in cold PBS 
and incubated 15' on ice. Then, the glutaraldehyde was aspirated and washed 3 times with 
PBS. 1mL of Sodium Borohydride (NaBH4) 5mg/mL in freshly prepared PBS was added 
and incubated at room temperature 3’. It was aspirated and washed 3 times with PBS. Under 
biosafety hood transfer the coverslips into a sterile 12-well. After coverslips sterilization 
with 70% ethanol for 15 min, 40,000 cells were seeded in 1mL complete medium/well and 
incubated for 24h. Cells were fixed in 4% PFA in PBS for 10'-15' at RT and without light. 
Then blocking with BSA (3% in PBS containing 0.1% Triton X-100) at same condition. Cells 
were stained with Phalloidin (1:250) in PBS containing 0.3% BSA and 0.1% Triton X-100) for 
30'-1h. Coverslips were mounted on a slide containing one drop of mount + DAPI. The 
results were observed with fluorescence microscope (Olympus BH-2 CCD). Quantification 
should be done on at least 15 fields per coverslip, generally at 40X, using all three channels. 
Quantification invadopodia activity: The black and white images related to the green 
channel were analysed with ImageJ. Then, the threshold was manually adjusted in order to 
detect only the areas actually corresponding to the degradation. The area fraction was 
measured and normalized over the number of DAPI cores in the same field to obtain the 
'normalized' area fraction. 
3.8. Construction of murine TRAP IL-1 plasmid 
 
For mIL1R1 mRNA from ID8 cell line was extracted using RNeasy kit (Qiagen Cat. No. 
74104) following manufacturer’s instructions and quantified. 1 ug of mRNA from ID8 cells 
was retrotranscribed using qScript cDNA synthesis kit (Cat. No. 95047-025) following 
manufacturer’s instructions. Amplicon of extracellular domain of mIL1R1 was obtained 
amplifying by PCR ID8 cells cDNA. The following primers were used for PCR amplification 
of mIL1R1: mIL1R1 FW 
CCGCTCGAGATGGAATGGAGCTGGGTCTTTCTCTTCTTCCTGTCAGTAACTACAGGT
GTCCACTCCCTGGAGATTGACGTATGTACAG and mIL1R1 RV: 
CTTACAACCACAATCCCTGGGCACGCTGCCGCCGCCACCACCAGAACCGCCACCG
CCCTTGAAGTCAGGGACTGGGT. After PCR amplification mIL1R1 amplicon was 
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isolated from gel using QIAquick Gel extraction kit (Cat. No. 28704) following 
manufacturer’s instruction and quantified.  
Amplicon for mFc was obtained amplifying by PCR using as template pIRES mTRAP 
(ERBB4-EGFR)-Fc98 kindly provided from Prof. Y. Yarden (Weizmann Institute of Science). 
The following primers were used for PCR amplification: mFc FW 
ACCCAGTCCCTGACTTCAAGGGCGGTGGCGGTTCTGGTGGTGGCGGCGGCAGCGT
GCCCAGGGATTGTGGTTGTAAG and mFc RV: 
GGGAGTTTGTGGAAAATTCTGAATGCATAGCGGCCGCTCATTTACCCGGAGTCCGG
GAGAAGC. Primers were specifically designed for the target sequences containing, XhoI 
and NotI-HF restriction sites, the leader sequence and a linker for mIL1R1 and mFc domain. 
mIL1R1 and mFc amplicons were first isolated using the QIAquick gel extraction kit 
(Qiagen, Cat. No.28704) and then fused by PCR obtaining the full-length mIL1R1-Fc 
3.9. Cloning and sequencing of mTRAP IL-1 insert 
 
mTRAP IL-1 insert was ligated into pIRES expression vector, amplified in bacteria, extracted 
and sequence analyzed by Sanger methodology. mTRAP IL-1 and pIRES mTRAP (ERBB2-
EGFR) plasmid vector were both double-digested with XhoI (New England Biolabs, R0146S) 
and NotI-HF (New England Biolabs, R3189S) restriction enzymes following the 
manufacturer's instructions and isolated from the gels.  
Subsequently, mTRAP IL-1 insert was ligated pIRES expression vector (pIRES mIL1R1-Fc) 
employing a T4 DNA ligase enzyme (New England Biolabs, M0202S) following the 
manufacturer's instructions. In order to amplifying the number of copies of pIRES mTRAP 
IL-1 plasmid DH5a competent cells (Invitrogen, Cat. No. 18265-017) were used and five 
different bacteria colonies (colonies 1-5) were randomly selected after over-night 
incubation. pIRES mTRAP IL-1 plasmid vector was isolated from bacteria using a mini-prep 
kit (Qiagen, Cat. No. 27104). pIRES mTRAP IL-1 plasmid vector isolated was used as 
template for PCR amplification. Primers specifically designed covering mTRAP IL-1 insert 
sequence (1751 bps size) were used: mTRAP IL-1 (Forward) 
ATAGGCTAGCCTCGAGATGG and mTRAP IL-1 (Reverse): 
CGGCCGCTCATTTACCAGGA. pIRES mTRAP IL-1 was double-digested with XhoI (New 
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England Biolabs, R0146S) and NotI-HF (New England Biolabs, R3189S) restriction enzymes 
following the manufacturer's instructions. mTRAP IL-1 plasmid vector was analyzed with 
Sanger technique for gap/mismatch detection. 
 
3.10. Expression and purification of TRAP IL-1 
 
A total of 1.000.000 HEK293T TRAP IL-1 cells has been seeded in T75 flask in DMEM 10% 
FBS. After reaching 80% confluence, cells have been splitted (1:10) and seeded in DMEM 
with 10% FBS concentration decreasing by 2% at every split (10%, 8%, 6%, 4% and 2%). 
DMEM 2% FBS has been replaced with a serum-free, protein-free, chemically-defined 
medium (CD293 medium for Suspension Cultures by Gibco Cat. No. 11913-019)) specifically 
formulated for HEK293T cultivation and recombinant protein expression, supplemented 
with 2% FBS. At this stage, cells detached and start growing in suspension, thus increasing 
the TRAP secretion. CD293 2% FBS has been replaced with CD293 0% FBS and cells grown 
at 37°C until reaching a high confluence, to burst TRAP production. After seven days soup 
has been collected for TRAP isolation. For TRAP isolation Protein G Sepharose™ 4 Fast Flow 
kit (from GE Healthcare, Lifescience) was used following manufacturer’s instructions. 
Briefly, soup has been collected and centrifuged (10.000g x 10 minutes) and filtered through 
a 0.45 um filter in order to eliminate gross contaminants (i.e. dead cells and debris). A poly-
prep column (Bio-RAD) has been packed with a resin of Protein G Sepharose™ containing 
beads specifically designed to strongly bind the Fc region of human IgG and extensively 
washed with 20 mM sodium phosphate buffer (pH 7). Soup containing TRAP IL-1 (sample) 
has been filtered throw the Protein G Sepharose matrix and the adsorbed TRAP IL-1 has 
been eluted with 0.1 M glycine solution (pH 2.7) and stored at -20°C for further analysis. 
Total amount and purity of proteins has been assessed by Lowry assay and Western Blot 
respectively.  
3.11. In vivo experiment and Hematoxylin-Eosin staining 
 
A total of 1x106 MC38 and MC38 mEGFR cells suspended in 0.1 mL of calcium- and 
magnesium free PBS per mouse has been injected subcutaneously (s.c.) in the left flank of 6- 
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to 7-week-old male wild-type C57BL/6 mice. Tumor growth has been evaluated by 
measuring two perpendicular diameters, length and width of tumor nodule with Vernier 
caliper, and calculated according to the following equation V=3.14x(LxW2)/6. After reaching 
the limiting volume (1500 mm3) mice were sacrificed and tumor were processed for 




4.1. Long-term exposure to antibody-mediated EGFR inhibition leads to the 
emergence of resistant cell clones 
 
We established cetuximab-resistant cells from the human colorectal cell line Caco-2, which 
is wild-type for KRAS, BRAF and NRAF, and dependent on EGFR as a mitogenic stimulus, 
as previously characterized99. Caco-2 cells were made resistant to CTX by continuous 
exposure over six months to increasing concentrations of the drug, ranging from 10 ng/ml 
to 20 µg/ml. We first confirmed resistance, by measuring cell growth using the Alamar 
assay. Caco-2 parental cells and CTX, hereinafter referred as parental (Caco-2 P), and 
cetuximab resistant (Caco-2 CXR) respectively, were treated with increasing concentrations 
of CTX for 72-96 hours and their proliferation was compared to cells treated with vehicle 
only (Fig. 10A). While parental cells displayed growth inhibition under CTX treatment, with 
maximal inhibition achieved at 1 to 5 µg/ml of the antibody, the resistant sub-line Caco-2 
CXR displayed undisturbed viability under CTX treatment, confirming acquired resistance 
(Fig. 10A). We next performed a long-term clonogenic assay, by seeding a very low number 
of cells in twelve well plates with the indicated treatments. After 10 days, the cells were 
fixed and stained with crystal violet, and clonogenic cell growth was evaluated by 
measuring the portion of covered area of the plate. In this assay, parental cells displayed a 
~50% and ~70% growth inhibition upon CTX treatment (Fig. 10B). In contrast, no change in 
clonogenic cell growth was detected in Caco-2 CXR clones. Finally, we performed the 
sequence analyses of KRAS exon, in order to test whether acquisition of KRAS mutation 
could explain the observed resistant phenotype. Interestingly, none of the CXR cells 




Figure 10: Establishment of colorectal cells resistant to cetuximab. Human colorectal cancer Caco-2 cells 
were made resistant to cetuximab (CTX) by continuous exposure to increasing doses of drug and maintained 
with 1 µg/ml of CTX. (A) Cell proliferation analysis by Alamar assay of Parental (Caco-2 P) and cetuximab-
resistant (Caco-2 CXR) cells following treatments with increasing concentration of cetuximab in medium 
containing 1% serum for 72h. The graphic represents the relative proliferation/viability of the cells following 
72 hours of treatment related to control; (B) Colony formation assay of Caco-2 P and Caco-2 CXR cells. Cells 
were grown in the absence or presence of CTX (1 µg/ml) for 10 days in medium containing 1% of serum, then 
fixed, stained with Crystal Violet and photographed. Representative figures (left) and quantification (right) of 
the covered areas by ImageJ is provided in B. The statistic was calculated by 2-way ANOVA, *** P<0.0001, ** 
P<0.01. These experiments were repeated at least three times. (C) Sequence analyses of KRAS Exon 2, showing 
the wild type sequence detected in Caco-2 Parental and Caco-2 CXR cells.  
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4.2. Resistant clones display anchorage-independent growth as spheroids 
 
The ability to grow in suspension is a hallmark of the neoplastic phenotype. Notably, only 
a small percentage, about 0.5% of Caco-2 from parental cells displayed the ability to grow 
in suspension and form spheroid-like structures. In contrast, more than 1.2% of CXR clones 
displayed the ability to form spheroids (Fig.11A). Statistically, parental cell spheroids were 
fewer and larger in size, when compared to CXR cells as depicted in the representative 
image (left) and quantification (right) of figure 11A. CTX treatments decreased sphere 
volumes in parental cells while CXR clones displayed no effects in terms of either spheroid 
size or number, supporting the lack of sensitivity of these cells to EGFR-targeting drugs (Fig. 
11A).  
Next, we investigated the morphology of the spheroids by embedding them into paraffin 
blocks, preparing 8-10 µm slides and staining them with haematoxylin-eosin (H&E). 
Parental cells displayed a well-organized architecture, with multiple layers of nuclei 
polarized on the external region and a hollow lumen filled with cell debris and matrix, as 
shown in Fig. 11 B-C and illustrated by Fig. 11D. On the other hand, CXR cells displayed 
poorly organized structures, with sparse nuclei in the entire volume and smaller and filled 
lumen (Fig. 11B and 11C). Furthermore, 3D rendering elaboration of the actin and nuclei 
signals, obtained by rotating the y axes and cutting the lower part of the spheroids helped 
to visualize the spheroid lumen, which appeared filled in the resistant cells (Fig. 11C). 
Summarizing, the CXR cells acquired a robust ability to grow in suspension. Parental 
spheroids are well organized and display a hollow lumen, whereas CXR spheroids are 
smaller, poorly organized and their lumen is filled or partially filled with cells. These 
findings support the notion that the adaptation to cetuximab lead to resistant clones 




Figure 11: Cetuximab resistant cells displayed increased ability to growth in suspension as colonspheres. 
We investigated the morphology of Caco-2 Parental and CXR cells when forced to grow in suspension. (A) On 
the left 4X magnification of Caco-2 producing “spheroid-like” structures, under the indicated treatments. Scale 
bar 100µm; on the right, number of filled spheroids presented as average ± S.E.M. 2-way ANOVA with 
Bonferroni Test, ** p<0.01; ****p<0.0001; Quantification of spheroids sizes measurements under the indicated 
treatments in 5% FBS (EGF 10 ng/ml, CTX 1 µg/mL ) is presented as dots plot. Each dot represents the 
quantification of a single spheroid (n= 117 for Parental cells, n=332 for CXR). Bar represents volume averages 
± S.E.M, 1-way ANOVA, ** p<0.01; ****p<0.0001; (B) Analysis of Caco-2 Parental and CXR paraffin-embedded 
spheroid morphology by H&E staining. Scale bar 50 µm; (C) Single section passing through the maximum 
diameter of spheroids and 3D confocal morphology of parental and CXR spheroids. Left panel: bright field 
imaging; central panels: DAPI and Phalloidin confocal microscopy; right panel: three-dimensional 
reconstructions of both signals, obtained by rotating the y axes and cutting the lower part of the spheroids 
(green lines) to observe the inner structures; scale bar 100 µm; (D) Illustration depicting a schematic 
representation of the parental and CXR spheroid morphology. 
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4.3. A module of inflammatory cytokines is induced in cetuximab resistant cells  
 
Secreted growth factors and cytokines have been shown to contribute to drug resistance by 
imparting compensatory survival cues 100–102. We sought to analyse the secretome of parental 
and resistant Caco-2 cells, in the presence or absence of cetuximab. The analysis included 
inflammatory cytokines (IL1A, IL1B, IL8), as well as critical components of positive ERBB 
feedback regulatory loops (such as the EGFR ligands TGFA, HBEGF), which were recently 
found to be involved in cetuximab resistance 103,104. To provide further functional annotation, 
we extended our analysis to specific negative feedback loops of the EGFR pathway, namely 
inhibitors of EGFR/ERBB signaling, such as LRIG1, LRIG3 and ERRFI1 105,106. Finally, the 
differentiation status of these cells was also tested by interrogating markers of the Epithelial 
to Mesenchymal Transition (EMT), such as E-cadherin, vimentin, SNAIL, LEF1 and SOX2 (a 
transcription factor associated with stemness) 107. 
The results are displayed in Fig. 12 as heat-maps, with red boxes corresponding to relatively 
high expression of the respective transcript and green boxes correspond to low expression. 
Under monolayer conditions, EGFR inhibition by cetuximab in parental cells led to a slight 
expression of IL1A, IL1B, IL8; while, these cytokines were markedly overexpressed in 
cetuximab-resistant clones (Fig. 12A). Similarly, the autocrine ligands HB-EGF and TGFa 
were upregulated in cetuximab-resistant clones (Fig. 12A). Resistant cells also featured 
increased levels of markers of epithelial-mesenchymal transition and stem-like features, 
with reduced expression of CDH1 (E-cadherin) and increased expression of vimentin, the 
EMT inducer SNAIL, and the stem-cell transcription factors LEF1 and SOX2 (Fig. 12A). 
Finally, resistant cells had increased levels of negative feedback regulators, most probably 
as a consequence of increased EGFR pathway deregulation (Fig. 12A). 
Most of the transcriptional modulations that occurred in 2D resistant cells could be also 
observed in resistant spheroids (Fig. 12B), indicating maintenance of these traits irrespective 
of culture conditions. Acquired production of the positive feedback components, such as 
HB-EGF and simultaneous inhibition of EGFR by negative feedback might reflect a shift 
toward HER2 heterodimer activation, as previously reported 108,109. 
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Of note, spheroids from parental cells did not experience any obvious transcriptional 
reprogramming following exposure to cetuximab, apart from increased expression of some 
EGFR negative regulators. The weak transcriptional consequences of EGFR blockade in 
parental spheroids could be related to initial selection of cells growing in suspension, which 
might have enriched for clones that are resistant to any kind of pro-apoptotic insult, 
including anchorage-independent growth and EGFR blockade. Analyses of the signalling 
pathways downstream to EGFR helped us to characterize signalling differences between 
Parental and CXR cells. Indeed, while parental cells responded to CTX treatment, by 
decreasing both phosphorylation of AKT and ERK (Fig. 12C), resistant cells appeared not 
sensitive to CTX inhibition on AKT phosphorylation. Interestingly, the basal level of pERK 
was in general higher in resistant cells, and CTX displayed his inhibitory capability on 
pERK, although less effective (Fig. 12C). Collectively, this analysis shows that the resistant 
phenotype is accompanied by increased expression of inflammatory cytokines and EGF-like 
growth factors, feedback activation of EGFR negative regulators, and EMT/stem-like 
features. 
These data are further supported by the evidence that EGFR activation in epithelial cells, 
such as MCF10A human mammary cells, immediately produce a module of inflammatory 
cytokines, namely IL1B, IL8 and CXCL1, by active transcriptional production (Fig. 13A). 
Furthermore, co-treatment with Dexamethasone (DEX), a powerful anti-inflammatory 
agent, dampened this production, pointing to a direct involvement of the EGFR pathway in 
the induction of an inflammatory-like response (Fig. 13A). Because EGF simultaneously up-
regulated several inflammatory cytokines, we assumed that the inflammation-regulating 
transcription factor, NF-κB, is stimulated by EGF in the mammary epithelial cells we 
employed. In line with this model, we observed concentration-dependent activation of NF-
κB (p65) by EGF (Fig. 13B). To extend these observations to the protein level and also to 
assay additional cytokines, we utilized a cytokine array (Fig 13C-D). This analysis detected 
high basal levels of IL-1a in untreated cells, which was increased following EGF stimulation 
and dampened by the DEX co-treatment. Interestingly, IL-1b, IL-8 and CXCL1 displayed 
very low basal levels with strong induction upon the growth factor stimulus, and once again 
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the anti-inflammatory action of DEX was able to block production of these cytokines.  
Figure 12: Gene expression analysis of parental and CXR cells. (A-B) PCR analysis of parental or cetuximab 
resistant (CXR) cells growing as monolayer (A) or as spheroids (B) were collected, both under CTX (2µg/ml) 
treatment or regular medium conditions. A set of genes probing EGFR positive/negative feedback loop, EMT 
phenotype and inflammatory cytokines were analysed and displayed as heatmap. (C)  Western blot analysis 
of phospho-AKT (pAKT), AKT, phospho-ERK (pERK) and ERK levels in Caco-2 Parental and CXR cells treated 
over-night with and without cetuximab. Actin served as a loading control. 
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Figure 13: EGFR activation controls the production of a module of inflammatory cytokines in MCF10A. (A) 
Expression levels of the module of inflammatory cytokines (IL1B and IL8 and CXCL1) analysed by Real-Time 
PCR in MCF10A following EGF (10 ng/mL) or DEX (100 nM) administration, alone or in combination, over a 
time course of 4h; (B) Western blot of NF-kB in cytoplasmic and nuclear fraction of MCF10A cells following 
administration of increasing doses of EGF (from 1 to 100 ng/ml). TNF-a (1 ng/ml) treatment was used as 
positive control for NF-kB (p65) activation and nuclear translocation. Laminin B and HSP90 were used as 
loading control for the nuclear and cytosolic fraction, respectively; C and D) Cytokine array of MCF10A cells 
following administration of EGF (10 ng/mL), DEX (100 nM), alone or in combination. Representative pictures 
are provided in (C). Quantification of chemioluminescence along with images of normalized spots are 




4.4. Analysis of patients’ specimens 
  
Our data in vitro pointed out the increased expression of a panel of inflammatory cytokines 
in cells resistant to cetuximab. We therefore decided to analyse the panel of selected 
cytokines in patients colorectal xenograft. Gene expression information was analysed in 
colorectal tumorgrafts from 98 patients with wild type KRAS, BRAF, NRAS, and PIK3CA 
genotypes (“quadruple negative” tumours) and from 61 individuals with KRAS (G12) 
mutations. KRAS G12 mutations lead to a constitutively activated K-Ras protein, which 
confers an intrinsic resistance to EGFR blockade. WT quadruple negative tumorgrafts were 
tested for cetuximab response, as described by Bertotti (Bertotti et al. 2011b). In this 
condition, the human stroma is supposed to be substituted by murine components; 
therefore, this analysis covers only receptors and autocrine ligands expressed by cancer 
cells110. Interestingly, we observed an inverse association between elevation of inflammatory 
cytokines IL1A, IL1B and IL8 and the overall response to cetuximab (Fig. 14). In accordance 
with our in vitro data, IL1A, IL1B and IL8 were overexpressed in tumorgrafts that proved to 
be resistant to EGFR blockade (tumor volume increase of at least 35% compared to the 
initial, pre-treatment volume). Furthermore, IL8 expression appeared over represented also 
in a group with limited sensitivity to cetuximab, with tumour volume changes between 35% 
increase and 50% reduction, which is considered as stable disease (SD). Interestingly, the 
pattern of increased expression of this module of inflammatory cytokines was maintained 
in the group of KRAS mutant tumours, which by definition are resistant to treatment. These 
results suggest that gradual tumour adaptation to EGFR blockade might be associated with 
up-regulation of the module of inflammatory cytokines, which might activate a 




Figure 14: A panel of inflammatory cytokines correlates with cetuximab response in colorectal patients. 
Expression analysis of IL1A, IL1B and IL8 in colorectal quadruple wild type (wild type for KRAS, BRAF, NRAS 
and PIK3CA) tumors, subdivided by response to Cetuximab therapy: disease regression (PR), disease 
stabilization (SD), disease progression (PD). The KRAS (G12 Mut) group was included as control for lack of 
response to CTX; 
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4.5. Overexpression of IL-1R1 correlates with reduced patient sensitivity to 
cetuximab 
 
Several clinical studies indicate that overexpression of inflammatory cytokines, such as 
IL-1, IL-8, IL-6 or CXCL1, correlates with cancer progression and decreased response to 
EGFR targeting therapy 111,112. We previously reported that the abundance of IL-1 cytokines 
predicts sensitivity to EGFR blockage 68. To further assess the clinical relevance of our 
results, we explored whether the receptor for IL-1, namely IL-1R1, was enriched in tumors 
from patients exhibiting attenuated response to anti-EGFR antibodies. We started by mining 
the gene expression profile from a publicly available microarray data set, comprising KRAS 
wild-type CRC patients, treated with cetuximab monotherapy, as described by Khambata-
Ford et al. 113 (GSE5851). Only one sample was excluded, because of its uncertain rectal 
origin. We observed that IL-1R1 is overexpressed in a distinct subpopulation of patients 
categorized as progressive disease (PD), defined as an increase in tumor burden upon CTX 
treatment. Consistently, patients with stable disease (SD) or an overall response (OR) to CTX 
therapy displayed lower IL-1R1 expression than the non-responding patients (Fig. 15). In 
line with our previous work 68, we conclude that increased expression of both IL-1 ligands 
(IL-1a and IL-1b) and receptor (IL-1R1) is associated with resistance to EGFR targeted 
therapy. 
Next, we evaluated the association of IL-1R1 with AREG and EREG, two EGFR ligands 
whose expression was previously reported to determine CTX efficacy. Indeed, high levels 
of AREG and EREG are predictive of response to CTX 113 , whereas high levels of IL-1R1 are 
predictive of poor response. Pearson analysis reported a moderate negative correlation 
between IL-1R1, AREG and EREG (-0.50, p=0.00057 and -0.44 p=0.003308 respectively): 
Table 1. These data support the notion that IL-1R1 is a marker of decreased patient 
sensitivity to CTX blockage, pointing to a role of this pathway in the progression and 
aggressiveness of colon cancer. 
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Figure 15: IL-1R1 abundance predicts response to CTX in patients. Expression analysis of IL-1 receptor in 67 
CRC patients treated with CTX. Responsive patients (OR) as well as stable disease (SD) display low amounts 
of IL-1R1 compared to the non-responsive patients (PD). The differences in IL-1R1 expression between 
individual groups (OR/SD/PD) were determined by one-way analysis of variance (ANOVA), followed by 
Fisher LSD test. 
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4.6. A recombinant decoy containing IL-1R1 inhibits growth in vitro 
 
To address the question whether intercepting “IL-1” cytokines (which refers both to 
alpha and beta isoforms in the following text), would improve response to EGFR-targeted 
therapies, we developed an engineered cell system producing a soluble receptor, named 
hTRAP IL-1, comprising the extracellular domain of human IL-1R1 linked to a soluble 
human Fc domain of immunoglobulin G as previously described 98. 
This IL-1 inhibition strategy assumes that the ligand-binding specificity of IL-1R1 would 
be able to sequester the majority of IL-1 ligands, thereby intercepting essential 
autocrine/paracrine loops. As an initial step, we designed a construct of the IL-1R1 binding 
domain fused to a six-histidine tag (Fig. 16A). Then, we stably transduced this construct in 
CRC Caco-2 cells (TRAP IL-1 cells). By Elisa assay, we confirmed that TRAP IL-1 was able 
to bind specifically the cognate ligands IL-1a and IL-1b (Fig. 16B).  
Analyses of total cell lysate showed the successful stable integration of hTRAP IL-1 (Fig. 
17A), which was secreted in the growing medium of TRAP IL-1 stable clones, whereas the 
Caco-2 control cells (Fc) displayed no product (Fig. 17B). Importantly, Fc cells displayed 
undisturbed proliferation and partially responded to CTX treatment, while TRAP IL-1 cells 
displayed impaired proliferation and enhanced ability to respond to CTX treatment (Fig. 
Figure 16: TRAP IL-1 recombinant decoy is able to bind IL-1A/B. (A) Design of the recombinant decoy 
hTRAP IL-1 depicting Fc, IL-1R and signal peptide subunits. Fc domain is a human immunoglobulin G. IL-1R 
subunit is the IL-1 binding site of human IL-1 receptor and signal peptide for the extracellular localization. 
Once TRAP IL-1 is secret from the cells, intercept IL-1 (both IL-1a and IL-1b) from the tumor environment 
preventing his agonist action. (B) Elisa assay testing the ability of three TRAP IL-1 clones, here referred to as 
TRAP 1/2/3, to specifically bind purified IL-1a/b. Briefly, 96 wells plates were coated with IL-1a and IL-1b and 
hTRAP IL-1 medium was added. After incubation, medium was washed out, and absorbance was detected. 
DMEM with 10% FBS and Goat serum served as negative control, a commercial anti IL-1a antibody was used 
as positive control. 
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17C). Next, we tested several colonies for the amount of secreted TRAP IL-1 in the medium. 
In detail, medium was collected after five days in culture and analyzed by western blot. 
Purified TRAP IL-1 (diluted at 10 ug) was used as a positive control (Fig. 17D). The 
proliferation capability and cell death in TRAP IL-1 clones was then evaluated and reported 
(Fig 17E). Interestingly, TRAP IL-1 positive clones displayed decreased proliferation (Fig. 
17E), without significant changes in cell death (Fig. 17E), thereby excluding a toxic effect of 
the secreted TRAP IL-1. We then employed one of the clones characterized by high TRAP 
IL-1 production, for further phenotypical evaluations, confirming that cells stably 
overexpressing the TRAP IL-1 display impaired growth compared to the Fc control (Fig. 
17F). These in vitro data support TRAP IL-1 adjuvant role in inferring with cell proliferation 




Figure 17: A recombinant decoy containing IL-1R1 inhibits Caco-2 growth. (A) Western Blot analysis of 
Caco-2 TRAP IL-1 and Fc. Actin served as loading control. 500k cells were plated in medium with 10% FBS, 
then cells were starved overnight (DMEM 0% FBS). The day after cells were harvested, total proteins extracted 
and quantified. Anti- IgG, Fcγ Fragment Specific human receptor monoclonal antibody was used for TRAP 
IL-1 detection. (B) Western blot analysis of three replicates of Caco-2 Fc and Caco- TRAP IL-1 soup. 500k cells 
were plated in DMEM supplemented with 10% FBS and after 5 days the soup was harvested and 20 µL used 
for Western Blot analysis. (C) Colony-forming assay of Caco-2 Fc and Caco-2 TRAP IL-1. 4000/well were 
plated and grown in the absence or presence of CTX (5 µg/mL) for 10 days in medium containing 10% of 
serum. Then fixed, stained with crystal violet and photographed. Representative figures (left) and 
quantification (right) of the covered areas by ImageJ are provided. The statistic was calculated by 2-way 
ANOVA, *** P<0.0005. These experiments were repeated at least three times. (D) Western Blot analysis of 
Caco-2 TRAP IL-1 clones soup. 1.35 – 1.44 – 1.47 – 1.11 and 1.51 are clones derived from a single cell. Each 
clone soup was collected 4 days after seeding. TRAP (purified protein) and Fc are intended as positive and 
negative controls respectively. (E) Clones from D were seeded and both living and death cells were counted. 
Statistical analysis was performed by one-way Anova, comparing the mean of proliferation of each clone to 
the control cells. Dunnet correction for multiple comparisons was applied. **** P<0.0001. (F) Cell count of 
Caco-2 Fc and Caco-2 TRAP IL-1 (clone 1.35). 100k/petri were seeded with 10% of serum. After 24h medium 
was changed with 10% of serum in the presence or absence of CTX (5 µg/mL) and cells were counted after 
24, 48 and 72 hours. A 2-way Anova was performed, by comparing the matched values for each time point 
(24, 48 and 72 h) to the Fc control cells. **** P<0.0001. 
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4.7. TRAP IL-1 clones display decreased cancer cell spheroidogenesis in 3D 
 
We sought to identify the phenotype of TRAP IL-1 in a defined 3D microenvironment, 
based on the lack of attachment to the plastic tray and forcing the cells to grow as spheroids. 
Fifteen days after suspending single cells in EGF supplemented medium, Fc cells formed 
hollow lumen cysts (Figure 18A). Similarly, TRAP IL-1 expressing cells were also able to 
form spheroids cyst-like structures, but these appeared rounded and smoother than the Fc 
counterpart (Fig. 18A). Next, we evaluated the Fc derivative both for colonsphere size and 
number. Fc appeared smaller than TRAP IL-1, which on the counterpart retained a 
decreased ability to form spheres (Fig. 18B). Indeed, by measuring more than 200 spheroids 
per condition, we found that the average size of TRAP IL-1 was larger than Fc, but the 
number of spheres was significantly lower (Fig. 18C). 
By confocal microscopy, we analyzed the inner organization of Fc and TRAP IL-1 
spheres. Fc spheres appeared loose and with low nuclear density on the outermost layer, 
while TRAP IL-1 displayed a pronounced nuclear density and an overall organization, 
suggesting an increased cell polarity. Fc displayed enhanced actin accumulation at the 
internal surfaces lining the central cavity, with a clear lumen, which was present in the 
majority of the cells.  
These results are in line with previous reports by time-lapse microscopy suggesting that 
the hollow lumen occurs through a process of internal expansion without cell proliferation 
or cell death 114,115. On the other hand, TRAP IL-1 still retained a wide and hollow lumen, 
but the cyst-like formation was much more emphasized in comparison to the control, while 
the ability of forming spheres was dramatically decreased in these cells (Fig. 18B-D). These 
data suggest a role for the TRAP IL-1 decoy in impacting on CRC growth both in 





Figure 18: Caco-2 TRAP IL-1 displays decreased growth in suspension as colonspheres.  (A) 4X magnification 
of Caco-2 Fc and Caco-2 TRAP IL-1 producing “spheroid-like” structures, under the indicated treatments. Scale 
bar 100 µm. (B) Number of filled spheroids presented as average ± S.E.M. 2-way ANOVA with Bonferroni Test, 
** p<0.01; ****p<0.0001; (C): Quantification of spheroid size measurements under the indicated treatments in 10% 
FBS supplemented with EGF 10 ng/mL and CTX 5 µg/mL. Columns represent volume averages ± S.E.M, 1-way 
ANOVA, ** p<0.01; ****p<0.0001; (D) 3D confocal microscopy of colonspheres Fc and TRAP IL-1. In the left panel 
is reported the DAPI and phalloidin staining. In the middle panel are featured single optical sections collected at 
15 µm intervals.  In the panel on the right, the xz optical section passing through the maximum diameter of the 
spheroids (upper part) and 3D rendering focused on the nuclear density and z-depth of the spheroids (yellow 
square), reported as a scale of colors, red indicates a 5 µm depth and blue 35 µm depth (bottom part). 
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4.8. IL-1 pathway inhibition impairs MAPK signaling 
 
In order to verify if the functional secreted and soluble TRAP IL-1 was able to neutralize 
IL-1 ligands, we treated Fc and TRAP IL-1 cells with IL-1a (10 ng/mL) over a long-time 
course, up to 24 hours. We analyzed both the mitogen activated protein kinase (MAPK) and 
the AKT axes. IL-1a treatment displayed an immediate mild activation of both ERK and 
AKT signals, followed by a secondary enhanced and delayed activation, as reported in the 
quantification in figure. 19B. According to these results, TRAP IL-1 was able to nullify the 
action of IL-1 on MAPK signaling activation, thus proving an effective neutralization of IL-
1 stimulus in vitro. Furthermore, TRAP IL-1 production spared the basally active ERK and 
AKT. Interestingly, both ERK and AKT displayed a bimodal activation (Fig. 19B), which 
was also blunted by TRAP IL-1. Next, we tested the abundance and the activation of EGFR 
under IL-1a stimulus, by measuring the phosphorylation of tyr1068. We detected an 
increase in EGFR abundance and phosphorylated EGFR upon 3 hours of IL-1a treatment. 
This effect could be related to an impaired degradation followed by a fast recycling of the 
receptor to the cell surface, a phenomena well described under TNFa or UV stress 116. 
Secondarily, we detected a new hit of phospho-EGFR at 12 hours of treatment, which was 
not followed by an enhanced EGFR protein, and it was consistent with the bimodal 
activation of MAPK and AKT. These data suggest that IL-1 boosts EGFR levels and that a 
positive feedback loop engaged by IL-1R1 stimulation may be responsible for sustaining the 
MAPK and AKT signals, through secondary activation of EGFR pathway. TRAP IL-1 was 
able to blunt EGFR production with a very low amount of pEGFR, an effect attributable to 
a decreased EGFR abundance, which might explain an overall lower activation of the 
downstream signaling pathways (Fig. 19A and C).  
Moreover, TRAP IL-1 is influencing endogenous expression of IL-1R1, which is stable 
in control cells under IL-1 treatment, but it appears downregulated in TRAP IL-1 cells. We 
speculate that this is the consequence of a chronic sequestration of IL-1 that might be 
responsible for a loss of dependency from this receptor in this cell system (Fig. 19C). 
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To sum up, these results indicated that secreted TRAP IL-1 molecules successfully 
dampen EGFR abundance and lead to a decreased activation of ERK and AKT. 
Figure 19: Bimodal activation of ERK and AKT after stimulation with IL-1A.  (A) Western blot analysis of 
phospho-AKT s473 (pAKT) and phospho-ERK (pERK) levels in Caco-2 Fc and Caco-2 TRAP IL-1 (time course). 
At day one, 500k cells were plated for each condition in medium with 10% FBS. At day 2, cells were starved 
overnight (DMEM 0% FBS) and the day after IL-1A (final concentration 10 ng/mL) was added to the medium 
of growing cells for 1, 3, 6, 8, 12 and 24 hours. After treatment cells were harvested, total proteins extracted and 
quantified. Monoclonal antibody against total AKT and ERK1/2 served as loading control. (B) Quantification 
of pAKT and pERK by Image Lab is provided. (C) Western blot analysis of phospho-EGFR Tyr1068, EGFR and 
IL-1R1 in Fc and TRAP IL-1 cells treated as in A. B-actin served as loading control. 
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4.9. IL-1 receptor abundance predicts relapse-free survival in CRC patients 
 
IL-1a and IL-1b signal through the same receptor complex. The response is initiated 
when the ligand binds to its primary receptor subunit IL-1R1 81. The receptor contains 
extracellular immunoglobulin domains and a Toll/IL-1 receptor domain in the cytoplasmic 
portion. Binding of the ligand allows the recruitment of a second receptor subunit the IL-
1R1 accessory protein (IL-1RAP). Formation of the receptor heterodimer induces signaling 
because the juxtaposition of the two Toll/IL-1 receptor domains enables the recruitment of 
myeloid differentiation primary response protein 88 (MYD88), IL-1R1 associated kinase 4 
(IRAK4), tumor necrosis factor receptor-associated factor 6 and other signaling 
intermediates 91. In vitro, our data pointed to an involvement of IL-1 in tumor growth and 
the lack of response to EGFR interception. We further addressed the question of IL-1R1 
expression associated with CRC progression in patients by performing a bioinformatic 
study in a cohort of 2166 CRC patients 117. The Kaplan Meier estimated the fraction of CRC 
patients resected for colorectal cancer and having a follow-up of a period of 200 months. We 
compared the relapse free survival (RFS) of 1211 patients, by splitting the dataset according 
to each cut off level between the lower and upper quartile of the expression level of the IL-
1R1 gene. We computed false discovery rate (FDR) to correct for multiple testing, and 
accepted only results with a FDR below 5%. The initial analysis was not restricted to specific 
categories, and interrogated the entire dataset. We distinguished two sets of patients with 
high and low IL-1R1 mRNA (probe 202948_at) expression respectively, and the association 
with patient survival. High levels of IL-1R1 were predictive of a worse disease-free survival 
and death with an HR of 1.75 and P-value of 1.6 e^-06. Median relapse-free survival was 21 
months and 66 months in the low and high IL-1R1 expression cohort, respectively. 
These results highlight the role of IL-1R1 in CRC patients and suggest that IL-1R1 
interception could represent an effective clinical strategy to improve prognosis and 
survival. Next, we attempted to stratify colorectal tumors into unique features according to 
their genetic profiles. We employed the consensus molecular subtype (CMS) as classified by 
Guinney et al. 45. They showed a marked interconnectivity among six independent 
classification systems coalescing into four CMSs with distinguishing features; CMS1 
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(microsatellite instability-immune), covering about 14% of CRC tumors, CMS2 
encompassing the canonical subtype with epithelial markers, CMS3 characterized by a 
metabolic dysregulation, and CMS4 with TGFβ activation, stromal invasion and 
angiogenesis. The abundance of IL-1R1 appears higher in CMS4 and CMS1, than in CMS2 
and CMS3 (Fig. 20B). IL-1R1 had a strong impact on patient survival in the CMS1 subtype 
(Fig. 20C), with an impressive HR of 2.74 and P-value: 0.00036. We then employed the de 
Sousa stratification, which associates patients with three distinguished colon cancer 
subtypes (CCS) CCS1, CCS2 and CCS3. CCS1 patients have the lowest risk of recurrence 
after tumor resection compared to patients belonging to the other subtypes 41. Interestingly, 
IL-1R1 overexpression is associated with more aggressive subtypes (Fig. 20D), with a strong 
association in CSS2, HR of 2.9 and P-value: 8.5*e^-05 and in CSS3 HR of 1.55 P-value: 0.016 
but in this case FDR was over 50%, whereas no subtypes 41 association was found for CSS1. 
Notably, IL-1R1 overexpression is also predictive of survival in the CSS3 subtype, which 





Figure 20: IL-1 receptor expression predicts survival in CRC patients. (A) A cohort of 1211 patients was 
divided into two groups according to IL-1 receptor abundance. In the Kaplan-Meier plot, the black line 
represents patients with an overall low IL-1R1 expression, while the red line represents subjects with high 
expression of IL-1R1. For each patient, the relapse free survival (RFS) is reported over time and expressed in 
months. (B) mRNA abundance of IL-1R1 in the four consensus molecular subtypes (CMS) subtypes. (C) 
Stratification of patients using the CMS criterion. Patients are divided into four subtypes. CMS1 (Immune): 
hypermutated, microsatellite unstable and strong immune activation. CMS2 (Canonical): epithelial, marked 
WNT and MYC signaling activation. CMS3 (Metabolic): epithelial and evident metabolic dysregulation. CMS4 
(Mesenchymal): prominent transforming growth factor-b activation, stromal invasion and angiogenesis. (D) 
KM plot of IL-1 receptor expression using de Sousa Classification of Colon Cancer subtypes. 
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4.10. HERK293T engineering with TRAP IL-1 and clones selection 
 
HEK293T cell line were engineered with a recombinant decoy namely Fc-IL1R1 (hereafter 
referred to as TRAP IL-1), which is able to sequester both IL-1a and IL-1b from the medium. 
Cells engineered with the recombinant protein containing only the Fc domain has been used 
as negative control (Figure 21A). From a heterogeneous population of engineered cells, we 
isolated single cell clones by serial dilution (Fig. 21A) and selected the most efficient TRAP 
IL-1 producing clone. As TRAP IL-1 is a soluble protein, we sought to verify the abundance 
of TRAP-IL1 in several clones medium. This assay was successfully applied to colon cancer 
cells (Caco-2) as reported in Gelfo et al., Cancers 201869, proving feasible obtaining cells 
secreting TRAP IL-1.  
  
Figure 21. TRAP IL-1 recombinant decoy is released in engineering HEK293T TRAP IL-1 medium. (A) 
Engineering of HEK293T cells with TRAP IL-1 and Fc (CTRL). HEK293T TRAP IL-1 cells have been seeded at 
single cell dilution, in a ninety-six-well plate following puromycin selection (1 ug/mL). After colony growth, 
cells have been transferred and expanded in six- well plates and T25 flasks. (B) Western blot of clones’ soup. 
500.000 cells for each clone has been seeded at day 1. After 5 days soup of different clones has been collected, 
centrifuged and tested for the presence of TRAP IL-1 using a human anti-Fc antibody. * Clones 2.C8.1 and 




Once the best TRAP IL-1 producing clones, namely HEK293T TRAP IL-1 2.C8.1 and 2F9.1 
(Fig. 21B) have been identified, TRAP IL-1 has been isolated from growing medium 
following the protocol detailed in figure 22A and material and methods section. Total 
amount and purity of TRAP IL-1 has been assessed by Western Blot (Fig. 22B) and 
quantified (Fig. 22C) 
  
Figure 22: Purification, control quality and quantification of TRAP IL-1 recombinant decoy. (A) graphical 
scheme depicting TRAP IL-1 isolation steps. For a detailed description of TRAP IL-1 isolation steps refer to 
material and methods section. (B) Western Blot analysis of TRAP IL-1 recombinant protein following isolation 
as in A. in details, lane 1 is the CTRL+, with a concentration of 27 µg/mL (diluted 1:20 from a mother stock of 
554 ug/mL). Lane 2 and 3, is TRAP IL-1 diluted 1:2 and not diluted respectively isolated following the protocol 
in A.  (C) TRAP IL-1 quantification was performed using ImageLab software calculating the volume of the 
bands compared to the CTRL+. 
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4.11. MC38 cell line engineered with the murine EGFR (mEGFR) and GFP 
 
To address the question whether intercepting IL-1 (which refers to both alpha and beta) 
would improve response to anti-EGFR therapies in vivo, we employed a murine colon 
adenocarcinoma MC38 cell line (kindly provided by Prof. M. Colombo, Istituto Nazionale 
Tumori). As MC38 cells line expresses EGFR at low level we transfected with murine Egfr 
(MC38_mEgfr). MC38_mEgfr cell line was employed for a syngeneic engraftment in 
C57BL/6N immunocompetent mice. 
After drug selection, from a heterogeneous cell population of engineered cells we isolated 
MC38 mEgfr single cell clones by serial dilution. Total mEgfr protein of the cell lysate of five 
MC38 mEgfr different clones (1.F6, 1.C3, 1.G11, 1.B3 and 1.F2) was tested (Fig. 23A). As 
shown in figure 23A MC38 control cells (MC38 CTRL-) displayed no mEgfr protein level 
while clone 1.C3.1 resulted as the best clone expressing mEgfr and, employed for 
subsequent experiments.  
Tumors heterogeneity has been addressed as the main culprit for multiple escaping 
mechanisms, reflecting the high level of molecular heterogeneity in each metastatic site. 
Metastasis formations include the dissemination of cancer cells from a malignant tumor and 
seed in distant sites inside the body and, for CRC patients lungs and livers are the major 
organs where metastasis disseminate. In order to evaluate whether intercepting IL-1 in 
combination with EGFR in vivo prevent metastasis formation, we obtained stable GFP- 
expressing MC38 and MC38 mEgfr cell lines. We infected MC38 and MC38 mEgfr with GFP 
viral particles and obtained respectively MC38 – GFP and MC38 mEgfr – GFP cell line as 
shown in figure 23B. In order to quantify the percentage of GFP expressing cells we 
analyzed MC38-GFP and MC38 mEgfr – GFP by cytofluorimetry. 46,14% of MC38 and 
41,76% of MC38 mEgfr resulted GFP positive.   
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Figure 23: MC38 and MC38 mEGFR cell line were engineered with GFP. (A) Western Blot analysis of MC38 
cell line engineered with murine Egfr (mEgfr). MC38 mEgfr mixed population was drug selected and plated 
in a 96 well plate for single cell dilution. Clones of MC38 mEgfr (1.F6, 1.C9, 1.C3, 1.G11, 1.B3, 1.E11, 1.F12, 1.D9 
and 1.D10) heterogeneous population clones were tested for Egfr level. Clone 1.C3 was chosen for subsequent 
experiments (B) Photos depicting bright field (TRANS) and GFP channel of MC38 (CTRL) MC38 – GFP and 
MC38 mEgfr – GFP (clone 1.C3). (C) quantification of GFP-positive MC38 and MC38 mEgfr cells by 
cytofluorimetry. 50.000 events were detected for each condition. 
 64 
4.12. MC38 engineered with murine EGFR displayed a more migratory and 
invasive phenotype  
Next, we characterize the invasive phenotype of MC38 mEgfr, in vitro. For this reason, 
we performed a scratch-wound assay comparing MC38 naïve cell with MC38 mEgfr cells 
following the wound healing for 12 hours. In these settings, we observed that MC38 mEgfr 
displayed a more invasive phenotype when compared to MC38 control cells as shown from 
the quantification panel (Fig. 24B). Accordingly, the invasive phenotype was detected 
through a Gelatin Degradation Assay, where cellular invasion is evaluated by gelatin 
degradation. This assay is designed to quantify invadopodia formation and activity 
indicating the ability of cancer cells to invade and metastasize. MC38 and MC38 mEgfr cells 
were seeded in a coverslip covered by a layer of gelatin for 24 hours. After, fixation and 
phalloidin and DAPI staining, gelatin degradation was analyzed. In this setting MC38 
mEgfr cells displayed an impressive degradation of the gelatin represented by several large 
black area and quantification (Fig. 24C and D respectively). These data suggested that MC38 
mEgfr cell have a higher migratory phenotype and a striking invasive phenotype compared 
to MC38 naïve counterpart. 
Next, we sought to verify in vivo, whether IL-1 interception enhances response to CTX. 
As CTX is a chimeric mouse:human mAbs employed in the clinic for mCRC patients, its 
efficacy is specific for human EGFR only. C57/BL6 mouse model will allow us to study the 
interplay between tumor-derived IL-1 and the host immune system. In order to verify 
immunological compatibility of MC38 mEgfr cells in vivo settings, we inoculated C57BL6 
mice with MC38 and MC38 mEgfr cells and observed an initial slower growth of MC38 
mEgfr tumor compared to MC38 CTRL tumors, followed by a sustained growth after 18 
days from inoculation (Fig 24E). Next, we investigated the morphology of tumor tissue 
preparing 5 µm slides and staining with hematoxylin-eosin (H&E) (Fig. 24F). In H&E 
staining MC38 mEgfr tumor tissue displayed a very high cellular density when compared 
to MC38 tumor tissue as shown in the 20X magnification (Fig. 24F). This result corroborates 




Figure 24: MC38 mEGFR cells in vitro and in vivo characterization. (A-B) Scratch assay was performed in 
murine MC38 and MC38 mEgfr cell. 75.000 cells per well were seeded in a 96-well plate. The day after a wound 
has been created. After washed with PBS cell invasion was followed in time-laps for 12 hours. Representative 
images (A) and quantification (B) are provided. (C-D) Gelatin Degradation Assay of MC38 and MC38 mEgfr 
were seeded in a coverslip covered with a layer of gelatin for 24h. Cells were fixed stained with phalloidin 
and DAPI and gelatin degradation was detected. The fluorescent microscope detects Alexa 488 (Oregon 
Green), Alexa 568 (Phalloidin), and DAPI. Gelatin degradation is detected in the green channel (Oregon Green 
conjugated gelatin) as dark area against the bright green background (Gelatin). The statistic was calculated by 
T-student Test. (E) 1000.000 MC38 mEgfr and MC38 (CTRL) cells were inoculated on the right flank of C57BL6 
mice. Tumor volume was measured after 11, 14, 18, 24 days after cells inoculation. MC38 and MC38 mEgfr 
mice were sacrificed after reaching the limiting size (14 days and 24 days respectively). (F) MC38 and MC38 
mEgfr tumors were fixed in formalin and paraffin embedded.  5 um slides were obtained for Hematoxylin-




4.13. Engineering of a murine recombinant decoy comprising IL-1R1 
  
Next, we aimed to develop a recombinant decoy TRAP-Fc (namely TRAP IL-1) able to 
sequester IL-1 from tumour environment in immunocompetent C57BL/6 mice. TRAP-Fc is 
a technology already in place for several years. For example, a recombinant protein 
comprising ErbB-1 and ErbB-4 extracellular domain has been proved to inhibit tumorigenic 
growth of human cancer cells in athymic NCr-nude mice 98. Also, our previous studies 
proved that a functional secreted and soluble human TRAP IL-1 is able to dampen cells 
growth both in monolayer and 3D environment69. Unfortunately, a lack of immunological 
compatibility and strong immune host reactivity against human TRAP IL-1 was expected. 
For these reasons, we developed a murine version of human TRAP IL-1 (hereafter referred 
mTRAP IL-1). A schematic representation and sequence comprising the subunits of mTRAP 
IL-1 is shown in figure 25 A and B. Thus, we cloned in-frame, into pIRES expression vector, 
the extracellular domain of murine IL-1R1 and Fc domain of murine immunoglobulin G 
(mFc). mIL1-R1 and mFc were fused and inserted into pIRES plasmid. 
For the mIL-1R1 subunit, we performed a PCR employing as template ID8 cDNA library 
and employed specific primers designed as follows: XhoI restriction enzyme site, Kozak, 
leader and part of mIL-1R1 sequence for forward primer while part of mIL-1R1, liker and 
part of mFc sequence are present in reverse primer (Fig. 25B, lower part). We obtained mIL-
1R1 PCR product of 1068 bps, then extracted and purified from gel 
For the mFc subunit, we performed a PCR employing as template pIRES mTRAP (ERBB4-
EGFR)-Fc (kindly provided by Y. Yarden lab) and employed specific primers designed as 
follows: part of mIL-1R1, linker and part of mFc sequence for forward primer while in the 
reverse primer part of mFc and XhoI restriction enzyme site sequence (Fig. 25D, lower part) 
are present.  We obtained mFc PCR product of 771 bps, then extracted and purified from 
gel. Then, we fused mIL-1R1 and mFc (mTRAP IL-1 insert) by PCR obtaining the complete 




Figure 25: Engineering of pIRES mIL1R1-mFc vector. (A) Schematic representation of murine IL1R1 recombinant 
decoy (mIL1R1-Fc) depicting its ability to bind IL-1. (B) Linear structure depicting Kozak (red), leader (grey), Mus 
musculus IL1R1 extracellular domain (mIL1R1 yellow), linker (blue) and murine Fc domain of immunoglobulin G 
(mFc, green). (C) Mus musculus extracellular domain of IL1R1 (mIL1R1) obtained by PCR (upper part) using as 
template ID8 cDNA library. Schematic representation (lower part) of mIL1R1 depicting XhoI restriction site (white), 
Kozak (red), leader (grey), mIL1R1 (yellow), linker (blue) and starting sequence of mFc (mFc s.s.). (D) mus musculus 
Fc domain of immunoglobulin G (mFc) obtained by PCR (upper part) using as template pIRES mERBB4-EGFR-Fc 
plasmid98. Schematic representation (lower part) of mFc depicting mIL1R1 ending sequence (mIL1R1 e.s., yellow), 
linker (blue), mFc and NotI-HF restriction site. (E) mIL1R1 obtained fusing by PCR amplicon in C and D.  
 68 
4.14. mTRAP IL-1 insert ligation, amplification, and sequence analysis 
 
After we cloned mTRAP IL-1 insert into pIRES plasmid vector (Fig. 26A), as detailed in the 
Material and Methods section, we obtained the pIRES mTRAP IL-1 plasmid vector (Fig. 
26B). PCR of pIRES mTRAP IL-1 (template) was performed utilizing primers specifically 
designed covering mTRAP IL-1 insert (Fig. 26C PCR – bacteria colonies). From PCR 
amplification we obtained a specific band of 1751 bps from colony 1, 2, 4 and 5 while from 
colony 3 we do not obtain a specific band (Fig. 26C PCR-bacteria colonies lane 3). ). pIRES 
mTRAP IL-1 from colony 5 was chose for digestion with XhoI and NotI. After XhoI and NotI 
digestion we obtained a specific band of 1774 bps while in the CTRL a specific band was not 
detected (Fig. 26C Digestion). In order to exclude genetic aberration occurred during the 
cloning and amplification process we analyze the sequence of mTRAP IL-1 by Sanger 
technique. From Sanger analysis we excluded the presence of mismatch or gap in the entire 
sequence analyzed (Fig. 26D). 
Also, we engineered and drug selected HEK293 cell line with mTRAP IL-1 (HEK293T 
mTRAP IL-1) as this cell line is routinely used for antibody production and has the ability 
to fast growth in a serum-free, protein-free, chemically defined medium optimized for the 
growth in suspension and burst the production of recombinant proteins. In order to prove 
stable integration and production of mTRAP IL-1 protein into the cell medium we detected 
mTRAP IL-1 protein in the cell medium of HEK293 mTRAP IL-1 cells employing an anti-
mFc secondary antibody in non-denaturating condition (Fig. 26E). Purified mTRAP IL-1 





Figure 26: mTRAP IL-1 cloning. (A) pIRES mERBB4-EGFR-Fc plasmid was digested with XhoI and NotI 
restriction enzymes, (gel extracted (pIRES only) and ligated with mIL1-1R1 insert (pIRES mTRAP IL-1). (B) 
Schematic representation depicting pIRES mIL1R1-Fc obtained by ligation of mIL1R1 and pIRES vector. (C) 
pIRES mTRAP IL-1 plasmid vector was amplified in bacteria and extracted from five different bacteria colonies 
(1-5) and used as template for PCR amplification. Primers specifically designed covering mTRAP IL-1 insert 
sequence (1751 bps size) were used. pIRES mTRAP IL-1 from colony 5 was chose for digestion with XhoI and 
NotI. (D) Sanger analysis of mTRAP IL-1 sequence. (E) Western Blot analysis of HEK293 mTRAP IL-1 soup. 
20 uL of soup were employed for each denaturating and non-denaturating setting (CTRL-, 10% and 2%). Soup 
has been collected, centrifuged, and tested for the presence of TRAP IL-1 using a mouse secondary antibody 




4.15. IL-1 stimulus stabilizes EGFR activation in MCF10 cell line  
 
In order to study the mechanism of IL-1 in EGFR pathway, avoiding perturbation derived 
from tumor transformation, we employed MCF10A, a quasi-normal mammary cell line 
highly dependent on EGFR, representing a useful tool for study EGFR signaling68. Thus, we 
assessed the effect of IL-1A and IL-1B assuming an overlapping biological activity, 
analyzing EGFR and the two major axes controlled by EGFR, namely mitogen activated 
protein kinase (MAPK) and AKT. For these reasons, we treated MCF10A cells with IL-1A 
(10 ng/mL) alone or in combination with EGF, over a time course, up to 2 hours. IL-1A 
treatment displayed a specific pattern where pEGFR, pAKT and pERK showed lack of 
activation while total EGFR, under the same stimulus, displayed immediate activation with 
an increased protein level after 10 minutes maintained up to two hours of treatment with a 
peak after 120 minutes from stimulus (Fig. 27A). Interestingly, when IL-1a is combined with 
EGF, the activated form of EGFR (pEGFR) displayed an immediate peak after 10 minutes 
from stimulus and a delayed decrease until 60 minutes from stimulus when compared to 
EGF stimulus alone. Also, the downstream activated form of AKT (pAKT) and ERK (pERK) 
displayed a delayed decrease when compared to EGF stimulation alone, with an immediate 
strong peak after 10 minutes and slowly decreasing after 30- and 60-minutes culminating 
with a decay of the signal after 120 minutes, as reported in the upper panel of Figure 27A 
and quantification (Figure 27B). In order to assess the effect of IL-1 interception from the 
microenvironment, we employed the recombinant decoy TRAP IL-1, produced and isolated 
as detailed in figure 22A, and in material and methods section. TRAP IL-1 is able to 
sequester IL-1a and IL-1b from the microenvironment69. When TRAP IL-1 is employed in 
combination with EGF and IL-1B we can observe a mild decrease in pEGFR activation, 
compared to the EGF+IL1 stimulus. Also, the activated form of AKT is lower when 
compared to EGF in combination with IL-1 as shown in the panel (Figure 28A) and 
quantification (figure 26B). Overall, these results suggest that IL-1 can increase EGFR 
phosphorylation and downstream AKT and ERK signals. While, TRAP IL-1 neutralization 




Figure 27: IL-1B stimulation enhance EGFR expression in MCF10 cell line. (A) Western blot analysis of 
pEGFR/EGFR, pAKT/AKT and pERK/ERK levels in MCF10A cell line (time course). At day one 500k cells 
plated for each condition in DMEM/F12 (50/50) supplemented with 5% of horse serum (HS), EGF (20 ng/m) 
hydrocortisone (HC, 1 µg/mL ) and insulin (INS, 10 µg/mL), At day 2 cells were starved (deprived by  HS, 
HC, and INS)  over-night and the day after EGF (10 ng/mL) and IL-1a (10 ng/mL) was added alone or in 
combination to the medium of growing cells for 10, 30, 60 and 120 minutes. After treatments cells were 
harvested, total protein extracted and quantified. Monoclonal antibody against total GAPDH served as 





Figure 28: Interception of IL-1 axis restore EGFR level in MCF10 cells. (A) EGF (10 ng/mL), EGF + IL-1b (10 
ng/mL) and, EGF + IL-1b + hTRAP IL-1 (50 ng/mL) was added to the medium of growing cells for 10, 30, 60 
and 120 minutes. Seeding, starvation, protein extraction and quantification (B) were performed in the same 
fashion as reported in Figure 27. 
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4.16. IL-1 activates EGFR phosphorylation in Caco-2 CTX sensible cell line 
 
In order to unveil the role of IL-1 in the molecular mechanism of CTX-resistance we 
treated Caco-2 CTX-sensitive cells over a long-time course, up to 48 hours, with CTX 
alone or in combination with IL-1B. We analyzed the total and activated form of EGFR 
(EGFR and pEGFR respectively) and IL-1R1 axes. Under CTX treatment, and compared 
to the control,  pEGFR appeared blunted at 12 hours, but with a secondary activation at 
24 hours, while both EGFR and IL-1R1 displayed a peak of production after 1 and 12 
hours of treatment as displayed in the quantification panel of figure 29 B. On the other 
hand, Caco-2 cell line treated with CTX in combination with IL-1B displayed a specific 
pattern. pEGFR and IL-1R1 protein level increased after 30 minutes and 4 hours from 
the stimulus, by reaching the maximum level at 24 hours, while total EGFR protein 
remained in general lower compared to CTRL, for the entire time-course, as reported in 
the quantification panel of figure 29 D. Surprisingly, pEGFR/EGFR ratio under CTX and 
IL-1B combination, displayed a stronger activation with a peak immediately after 30 
minutes and a second and third hit after 4 and 24 hours from stimulus.  Overall, these 
results may suggest that IL-1B was able to nullify the action of CTX on pEGFR 
downregulation, thus suggesting an escape from the degradative faith.  
This effect could be related to an impaired degradation followed by recycling of the 









Figure 29: Western blot analysis of pEGFR, EGFR and IL-1R1 levels in Caco-2 cells (Time course). (A and 
C). At day one, 500k cells were plated for each condition in medium with 10% FBS. At day 2, cells were starved 
overnight (DMEM 0% FBS) and the day after CTX and/or IL-1B (final concentration 10 ug/mL and 10 ng/mL 
respectively) were added to the medium of growing cells for 0.5, 1, 2, 4, 8, 12, 24 and 48 hours. After treatment 
cells were harvested, total proteins extracted and quantified. Monoclonal antibody against total GAPDH 
served as loading control. Quantification of pEGFR, EGFR and IL-1R1 by Image Lab is provided (B and D). 





5. Conclusions and discussion 
 
The physiological role of ERBB receptors family is conserved through evolution accounting 
for vital cellular mechanisms such as development, survival, proliferation and 
differentiation. In higher eukaryotes, ERBB signal pathway has evolved from a linear 
pathway to a richly interactive, multi-layered network featured by  modularity and 
redundancy that contribute to the robustness of the signal1,118. Monoclonal antibodies 
blocking EGFR, such as CTX are employed in mCRC patient. Unfortunately, patients 
develop resistance to the drug leading to therapy failure. Several efforts have been spent to 
shed light in the molecular mechanisms implicated in the emergence of CTX resistance. The 
evidence we provided in this thesis, suggest that resistance to EGFR blockade, may depend 
on activation of an alternative pathway, namely IL-1R1. Indeed, our results suggest that IL-
1 derived from the microenvironment has a role in CTX responsiveness, by inducing the 
overexpression of IL1R1. In line with these findings, the expression level of IL-1 has been 
correlated with worst prognosis in many types of tumors. More recently, the employment 
of mAb, MABp1a against IL-1a, displayed a disease control in 18 different tumors types and 
its efficacy was further confirmed in a phase 3 clinical trial in a cohort of 333 advanced CRC 
patients76,119. Also the employment of Canakinumab, (an anti-IL-1b mAb) significantly 
reduced the incidence of lung cancer in a cohort of 10.061 patients120.  
We reported that CTX treatment is responsible for IL-1 production68 in vitro. In line, the 
subset of patients with progressive CRC presented higher levels of IL-1R1 compared to 
patients responsive to the therapy. Interestingly, IL1R1 abundance was also predictive of 
survival  specifically in CMS1, also known as the immunological subtype, mainly 
characterized by microsatellite instability54. Of note, CMS1 is characterized by increased 
expression of genes associated with a diffuse immune infiltrate, along with strong activation 
of immune evasion pathways55. Mechanistically, we showed that IL-1R1 stimulus by both 
IL-1a and IL-1b is responsible for a sustained MAPK and AKT activation, which may 
interfere with CTX inhibition of the pathways. Indeed, EGFR phosphorylation upon IL-1 
stimulus, displayed a persistent activation suggesting a cascade of signaling events ignited 
by IL-1 treatment. This model suggests a trans regulatory mechanisms mediated by IL-1 
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pathway activation that entail EGFR receptor phosphorylation, probably as evasion from 
the degradative fate. These data are in line with a model of recycling of EGFR consequent 
to cytokine stimulus as well as UV and tumor necrosis factor 116. Thus, we suggested a 
Cetuximab resistance-working model in mCRC patients (Fig 30). Furthermore, it may be 
closely linked to another important positive late feedback mechanism given by the autocrine 
loop, mediated by the MAPK pathway, that sustains growth factors signals such as tumor 
necrosis factor, IL-1a, and converts a transient stimulus into a sustained signal 123,124.  
Stemming from these observations, we developed a working strategy combining EGFR and 
IL-1 neutralization in vivo, to overcome the emergence of CTX resistance. In order to test this 
hypothesis, we developed the MC38 cell line engineered with murine EGFR, assuring a 
complete immunological compatibility with the C57/BL6 murine model. In line, we 
developed a murine version of TRAP IL-1. In the next future, we plan to test our hypothesis 
by combining murine TRAP IL-1 with anti-EGFR antibody in vivo. We expect that 
interception of IL-1R1 axis combined with EGFR blockade will have a beneficial effect in 




Figure 30: Cetuximab resistance-working model in mCRC patients. We proposed that upon cetuximab 
treatment the emergence of ressitance is sustained by activation of IL-1R1 alternative pathway. Our data 
suggest that in a context of CTX sensible cells, after CTX treatment (on the left)  EGFR is instated to the 
degradative fate dampening proliferation and survival paralleled by increased expression of IL-1 from the 
tumor itself. The autocrine and paracrine action of IL-1 in the tumor microenviroment suggest a  trans 
regolatory mechanisms  mediated by IL-1 that entail EGFR phosphorylation and evasion from the degradative 
fate (on the right). This in turn feed a positive feedback loop that lead to proliferation, survival, differentiation 
and epithelial-mesenchimal transition (EMT).  
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